Skip to main content
Erschienen in: Clinical Reviews in Allergy & Immunology 3/2017

16.07.2017

Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review

verfasst von: Caterina Ferreli, Giulia Gasparini, Aurora Parodi, Emanuele Cozzani, Franco Rongioletti, Laura Atzori

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Scleroderma refers to an autoimmune connective tissue fibrosing disease, including three different subsets: localized scleroderma, limited cutaneous systemic sclerosis, and diffuse cutaneous systemic sclerosis with divergent patterns of organ involvement, autoantibody profiles, management, and prognostic implications. Although systemic sclerosis is considered the disease prototype that causes cutaneous sclerosis, there are many other conditions that can mimic and be confused with SSc. They can be classified into immune-mediated/inflammatory, immune-mediated/inflammatory with abnormal deposit (mucinoses), genetic, drug-induced and toxic, metabolic, panniculitis/vascular, and (para)neoplastic disorders according to clinico-pathological and pathogenetic correlations. This article reviews the clinical presentation with emphasis on cutaneous disease, etiopathogenesis, diagnosis, and treatment options available for the different forms of scleroderma firstly and for scleroderma-like disorders, including scleromyxedema, scleredema, nephrogenic systemic fibrosis, eosinophilic fasciitis, chronic graft-versus-host disease, porphyria cutanea tarda, diabetic stiff-hand syndrome (diabetic cheiroartropathy), and other minor forms. This latter group of conditions, termed also scleroderma mimics, sclerodermiform diseases, or pseudosclerodermas, shares the common thread of skin thickening but presents with distinct cutaneous manifestations, skin histology, and systemic implications or disease associations, differentiating each entity from the others and from scleroderma. The lack of Raynaud’s phenomenon, capillaroscopic abnormalities, or scleroderma-specific autoantibodies is also important diagnostic clues. As cutaneous involvement is the earliest, most frequent and characteristic manifestation of scleroderma and sclerodermoid disorders, dermatologists are often the first-line doctors who must be able to promptly recognize skin symptoms to provide the affected patient a correct diagnosis and appropriate management.
Literatur
1.
3.
Zurück zum Zitat Elhai M, Avouac J, Walker UA, Matucci-Cerinic M, Riemekasten G, Airo P et al (2016) A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 75:163–169PubMedCrossRef Elhai M, Avouac J, Walker UA, Matucci-Cerinic M, Riemekasten G, Airo P et al (2016) A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 75:163–169PubMedCrossRef
4.
Zurück zum Zitat Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA Jr (2012) A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum 64:2986–2994PubMedPubMedCentralCrossRef Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA Jr (2012) A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum 64:2986–2994PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino AV Jr, Steen VD, Medsger TA Jr (2006) Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol 33:1004–1013PubMed Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino AV Jr, Steen VD, Medsger TA Jr (2006) Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol 33:1004–1013PubMed
7.
Zurück zum Zitat Gladman DD, Kung TN, Siannis F, Pellett F, Farewell VT, Lee P (2005) HLA markers for susceptibility and expression in scleroderma. J Rheumatol 32:1481–1487PubMed Gladman DD, Kung TN, Siannis F, Pellett F, Farewell VT, Lee P (2005) HLA markers for susceptibility and expression in scleroderma. J Rheumatol 32:1481–1487PubMed
8.
Zurück zum Zitat Radstake TR, Gorlova O, Rueda B et al (2010) Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 42:426–429PubMedPubMedCentralCrossRef Radstake TR, Gorlova O, Rueda B et al (2010) Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 42:426–429PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Distler O, Cozzio A (2016) Systemic sclerosis and localized scleroderma—current concepts and novel targets for therapy. Semin Immunopathol 38:87–95PubMedCrossRef Distler O, Cozzio A (2016) Systemic sclerosis and localized scleroderma—current concepts and novel targets for therapy. Semin Immunopathol 38:87–95PubMedCrossRef
10.
11.
Zurück zum Zitat Grabell D, Hsieh C, Andrew R, Martires K, Kim A, Vasquez R et al (2014) The role of skin trauma in the distribution of morphea lesions: a cross-sectional survey of the morphea in adults and children cohort IV. J Am Acad 71:493–498CrossRef Grabell D, Hsieh C, Andrew R, Martires K, Kim A, Vasquez R et al (2014) The role of skin trauma in the distribution of morphea lesions: a cross-sectional survey of the morphea in adults and children cohort IV. J Am Acad 71:493–498CrossRef
12.
Zurück zum Zitat Matucci-Cerinic M, Kahaleh B, Wigley FM (2013) Evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 65:1953–1962PubMedCrossRef Matucci-Cerinic M, Kahaleh B, Wigley FM (2013) Evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 65:1953–1962PubMedCrossRef
13.
Zurück zum Zitat Pattanaik D, Brown M, Postlethwaite AE (2011) Vascular involvement in systemic sclerosis (scleroderma). J Inflamm Res 4:105–125PubMedPubMedCentral Pattanaik D, Brown M, Postlethwaite AE (2011) Vascular involvement in systemic sclerosis (scleroderma). J Inflamm Res 4:105–125PubMedPubMedCentral
14.
Zurück zum Zitat Varga J (2008) Systemic sclerosis an update. Bull NYU Hosp Jt Dis 66:198–202PubMed Varga J (2008) Systemic sclerosis an update. Bull NYU Hosp Jt Dis 66:198–202PubMed
17.
Zurück zum Zitat Stern EP, Denton CP (2015) The pathogenesis of systemic sclerosis. Rheum Dis Clin N Am 41:367–382CrossRef Stern EP, Denton CP (2015) The pathogenesis of systemic sclerosis. Rheum Dis Clin N Am 41:367–382CrossRef
18.
Zurück zum Zitat van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) Classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755PubMedCrossRef van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) Classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755PubMedCrossRef
19.
Zurück zum Zitat Jaeger VK, Wirz EG, Allanore Y, Rossbach P, Riemekasten G, Hachulla E, Distler O, Airò P, Carreira PE, Balbir Gurman A, Tikly M, Vettori S, Damjanov N, Müller-Ladner U, Distler JH, Li M, Walker UA, EUSTAR Co-authors (2016) Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One 11:e0163894PubMedPubMedCentralCrossRef Jaeger VK, Wirz EG, Allanore Y, Rossbach P, Riemekasten G, Hachulla E, Distler O, Airò P, Carreira PE, Balbir Gurman A, Tikly M, Vettori S, Damjanov N, Müller-Ladner U, Distler JH, Li M, Walker UA, EUSTAR Co-authors (2016) Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One 11:e0163894PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Desbois AC, Cacoub P (2016) Systemic sclerosis: an update in 2016. Autoimmun Rev 15:417–426PubMedCrossRef Desbois AC, Cacoub P (2016) Systemic sclerosis: an update in 2016. Autoimmun Rev 15:417–426PubMedCrossRef
21.
Zurück zum Zitat Meier FM, Frommer KW, Dinser R et al (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR scleroderma trials and research group database. Ann Rheum Dis 71:1355e60CrossRef Meier FM, Frommer KW, Dinser R et al (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR scleroderma trials and research group database. Ann Rheum Dis 71:1355e60CrossRef
22.
Zurück zum Zitat Hughes M, Herrick AL (2016) Raynaud’s phenomenon. Best Pract Res Clin Rheumatol 30:112–132PubMedCrossRef Hughes M, Herrick AL (2016) Raynaud’s phenomenon. Best Pract Res Clin Rheumatol 30:112–132PubMedCrossRef
23.
Zurück zum Zitat Avouac J, Fransen J, Walker UA et al (2011) Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR scleroderma trials and research group. Ann Rheum Dis 70:476e81 Avouac J, Fransen J, Walker UA et al (2011) Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR scleroderma trials and research group. Ann Rheum Dis 70:476e81
24.
Zurück zum Zitat Minier T, Guiducci S, Bellando-Randone S, Bruni C, Lepri G, Czirjak L et al (2014) Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 73:2087–2093PubMedCrossRef Minier T, Guiducci S, Bellando-Randone S, Bruni C, Lepri G, Czirjak L et al (2014) Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 73:2087–2093PubMedCrossRef
25.
Zurück zum Zitat Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P et al (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20:1892–1896PubMed Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P et al (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20:1892–1896PubMed
26.
Zurück zum Zitat Barsotti S, Stagnaro C, Della Rossa A (2015) Systemic sclerosis: a critical digest of the recent literature. Clin Exp Rheumatol 33(Suppl. 91):S3–14PubMed Barsotti S, Stagnaro C, Della Rossa A (2015) Systemic sclerosis: a critical digest of the recent literature. Clin Exp Rheumatol 33(Suppl. 91):S3–14PubMed
27.
Zurück zum Zitat Czirják L, Nagy Z, Aringer M et al (2007) The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 66:966–969PubMedPubMedCentralCrossRef Czirják L, Nagy Z, Aringer M et al (2007) The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 66:966–969PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Hesselstrand R, Carlestam J, Wildt M, Sandqvist G, Andréasson K (2015) High frequency ultrasound of skin involvement in systemic sclerosis—a follow-up study. Arthritis Res Ther 17:329PubMedPubMedCentralCrossRef Hesselstrand R, Carlestam J, Wildt M, Sandqvist G, Andréasson K (2015) High frequency ultrasound of skin involvement in systemic sclerosis—a follow-up study. Arthritis Res Ther 17:329PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Santiago T, Alcacer-Pitarch B, Salvador MJ, Del Galdo F, Redmond AC, da Silva JAP (2016) A preliminary study using virtual touch imaging and quantification for the assessment of skin stiffness in systemic sclerosis. Clin Exp Rheumatol 34(Suppl. 100):S137–S141 Santiago T, Alcacer-Pitarch B, Salvador MJ, Del Galdo F, Redmond AC, da Silva JAP (2016) A preliminary study using virtual touch imaging and quantification for the assessment of skin stiffness in systemic sclerosis. Clin Exp Rheumatol 34(Suppl. 100):S137–S141
31.
Zurück zum Zitat Bajraktari IH, Kryeziu A, Sherifi F, Bajraktari H, Lahu A, Bajraktari G (2015) Oral manifestations of systemic sclerosis and correlation with anti-topoisomerase I antibodies (SCL-70). Med Arch 69:153–156PubMedPubMedCentralCrossRef Bajraktari IH, Kryeziu A, Sherifi F, Bajraktari H, Lahu A, Bajraktari G (2015) Oral manifestations of systemic sclerosis and correlation with anti-topoisomerase I antibodies (SCL-70). Med Arch 69:153–156PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Maddali Bongi S, Del Rosso A, Galluccio F, Tai G, Sigismondi F, Passalacqua M, Landi G, Baccini M, Conforti ML, Miniati I et al (2009) Efficacy of a tailored rehabilitation program for systemic sclerosis. Clin Exp Rheumatol 27:S44–S50 Maddali Bongi S, Del Rosso A, Galluccio F, Tai G, Sigismondi F, Passalacqua M, Landi G, Baccini M, Conforti ML, Miniati I et al (2009) Efficacy of a tailored rehabilitation program for systemic sclerosis. Clin Exp Rheumatol 27:S44–S50
33.
Zurück zum Zitat Silvestre-Rangil J, Martinez-Herrera M, Silvestre FJ (2015) Dental management of patients with microstomia. A review of the literature and update on the treatment. J Oral Res 4:340–350CrossRef Silvestre-Rangil J, Martinez-Herrera M, Silvestre FJ (2015) Dental management of patients with microstomia. A review of the literature and update on the treatment. J Oral Res 4:340–350CrossRef
34.
Zurück zum Zitat Crincoli V, Fatone L, Fanelli M, Rotolo RP, Chialà A, Favia G, Lapadula G (2016) Orofacial manifestations and temporomandibular disorders of systemic scleroderma: an observational study. Int J Mol Sci 17:1189PubMedCentralCrossRef Crincoli V, Fatone L, Fanelli M, Rotolo RP, Chialà A, Favia G, Lapadula G (2016) Orofacial manifestations and temporomandibular disorders of systemic scleroderma: an observational study. Int J Mol Sci 17:1189PubMedCentralCrossRef
35.
Zurück zum Zitat Jagadish R, Mehta DS, Jagadish P (2012) Oral and periodontal manifestations associated with systemic sclerosis: a case series and review. J Indian Soc Periodontol 16:271–274PubMedPubMedCentralCrossRef Jagadish R, Mehta DS, Jagadish P (2012) Oral and periodontal manifestations associated with systemic sclerosis: a case series and review. J Indian Soc Periodontol 16:271–274PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Aliko A, Ciancaglini R, Alushi A, Tafaj A, Ruci D (2011) Temporomandibular joint involvement in rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis. Int J Oral Maxillofac Surg 40:704–709PubMedCrossRef Aliko A, Ciancaglini R, Alushi A, Tafaj A, Ruci D (2011) Temporomandibular joint involvement in rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis. Int J Oral Maxillofac Surg 40:704–709PubMedCrossRef
37.
Zurück zum Zitat Denton CP (2015) Systemic sclerosis: from pathogenesis to targeted therapy. Clin Exp Rheumatol 33:S3–S7PubMed Denton CP (2015) Systemic sclerosis: from pathogenesis to targeted therapy. Clin Exp Rheumatol 33:S3–S7PubMed
38.
Zurück zum Zitat Pizzorni C, Giampetruzzi AR, Mondino C, Facchiano A, Abeni D, Paolino S, Ruaro B, Smith V, Sulli A, Cutolo M (2016) Nailfold capillaroscopic parameters and skin telangiectasia patterns in patients with systemic sclerosis. Microvasc Res 111:20–24PubMedCrossRef Pizzorni C, Giampetruzzi AR, Mondino C, Facchiano A, Abeni D, Paolino S, Ruaro B, Smith V, Sulli A, Cutolo M (2016) Nailfold capillaroscopic parameters and skin telangiectasia patterns in patients with systemic sclerosis. Microvasc Res 111:20–24PubMedCrossRef
39.
Zurück zum Zitat Smith V, Decuman S, Sulli A, Bonroy C, Piettte Y, Deschepper E et al (2012) Do worsening scleroderma capillaroscopic pattern predict future severe organ involvement? A pilot study. Ann Rheum Dis 71:1636–1639PubMedCrossRef Smith V, Decuman S, Sulli A, Bonroy C, Piettte Y, Deschepper E et al (2012) Do worsening scleroderma capillaroscopic pattern predict future severe organ involvement? A pilot study. Ann Rheum Dis 71:1636–1639PubMedCrossRef
42.
Zurück zum Zitat Nabil PA, Rao RA, Shrutakirti Shenoi D, Balachandran C (2006) Nail unit in collagen vascular diseases: a clinical, histopathological and direct immunofluorescence study. Indian J Dermatol 51:265–268CrossRef Nabil PA, Rao RA, Shrutakirti Shenoi D, Balachandran C (2006) Nail unit in collagen vascular diseases: a clinical, histopathological and direct immunofluorescence study. Indian J Dermatol 51:265–268CrossRef
43.
Zurück zum Zitat Tunc SE, Ertam I, Pirildar T, Turk T, Ozturk M, Doganavsargil E (2007) Nail changes in connective tissue diseases: do nail changes provide clues for the diagnosis? J Eur Acad Dermatol Venereol 21:497–503PubMed Tunc SE, Ertam I, Pirildar T, Turk T, Ozturk M, Doganavsargil E (2007) Nail changes in connective tissue diseases: do nail changes provide clues for the diagnosis? J Eur Acad Dermatol Venereol 21:497–503PubMed
44.
Zurück zum Zitat Sultan-Bichat N, Menard J, Perceau G, Staerman F, Bernard P, Reguia Z (2012) Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy. J Am Acad Dermatol 66:424–429PubMedCrossRef Sultan-Bichat N, Menard J, Perceau G, Staerman F, Bernard P, Reguia Z (2012) Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy. J Am Acad Dermatol 66:424–429PubMedCrossRef
45.
Zurück zum Zitat Johnstone EM, Hutchinson CE, Vail A, Chevance A, Herrick AL (2012) Acro-osteolysis in systemic sclerosis is associated with digital ischemia and severe calcinosis. Rheumatology 51:2234–2238PubMedCrossRef Johnstone EM, Hutchinson CE, Vail A, Chevance A, Herrick AL (2012) Acro-osteolysis in systemic sclerosis is associated with digital ischemia and severe calcinosis. Rheumatology 51:2234–2238PubMedCrossRef
46.
Zurück zum Zitat Avouac J, Mogavero G, Guerini H et al (2011) Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study. Ann Rheum Dis 70:630–633PubMedCrossRef Avouac J, Mogavero G, Guerini H et al (2011) Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study. Ann Rheum Dis 70:630–633PubMedCrossRef
47.
Zurück zum Zitat Koutaissoff S, Vanthuyne M, Smith V et al (2011) Hand radiological damage in systemic sclerosis: comparison with a control group and clinical and functional correlations. Semin Arthritis Rheum 40:455–460PubMedCrossRef Koutaissoff S, Vanthuyne M, Smith V et al (2011) Hand radiological damage in systemic sclerosis: comparison with a control group and clinical and functional correlations. Semin Arthritis Rheum 40:455–460PubMedCrossRef
48.
Zurück zum Zitat Giampetruzzi AR, Mondino C, Facchiano A, Bono R, Puddu P, Didona B, Abeni D, Cutolo M (2013) Association of dermoscopic profiles of telangiectases with nailfold videocapillaroscopic patterns in patients with systemic sclerosis. J Rheumatol 40:1630–1632PubMedCrossRef Giampetruzzi AR, Mondino C, Facchiano A, Bono R, Puddu P, Didona B, Abeni D, Cutolo M (2013) Association of dermoscopic profiles of telangiectases with nailfold videocapillaroscopic patterns in patients with systemic sclerosis. J Rheumatol 40:1630–1632PubMedCrossRef
49.
Zurück zum Zitat Hurabielle C, Avouac J, Lepri G, de Risi T, Kahan A, Allanore Y (2016) Skin telangiectasia and the identification of a subset of systemic sclerosis patients with severe vascular disease. Arthritis Care Res 68:1021–1027CrossRef Hurabielle C, Avouac J, Lepri G, de Risi T, Kahan A, Allanore Y (2016) Skin telangiectasia and the identification of a subset of systemic sclerosis patients with severe vascular disease. Arthritis Care Res 68:1021–1027CrossRef
50.
Zurück zum Zitat Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32–38PubMedCrossRef Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32–38PubMedCrossRef
51.
Zurück zum Zitat Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis 66:754–763PubMedPubMedCentralCrossRef Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis 66:754–763PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Almeida C, Almeida I, Vasconcelos C (2015) Quality of life in systemic sclerosis. Auto Immun Rev 14:1087–1096CrossRef Almeida C, Almeida I, Vasconcelos C (2015) Quality of life in systemic sclerosis. Auto Immun Rev 14:1087–1096CrossRef
53.
Zurück zum Zitat Denton CP, Krieg T, Guillevin L, Schwierin B, Rosenberg D, Silkey M et al (2012) De- mographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO registry. Ann Rheum Dis 71:718–721PubMedPubMedCentralCrossRef Denton CP, Krieg T, Guillevin L, Schwierin B, Rosenberg D, Silkey M et al (2012) De- mographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO registry. Ann Rheum Dis 71:718–721PubMedPubMedCentralCrossRef
54.
Zurück zum Zitat Brand M, Hollaender R, Rosenberg D, Scott M, Hunsche E, Tyndall A, Denaro V, EUSTAR Co-investigators et al (2015) An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database. Clin Exp Rheumatol 33(4 Suppl 91):S47–S54PubMed Brand M, Hollaender R, Rosenberg D, Scott M, Hunsche E, Tyndall A, Denaro V, EUSTAR Co-investigators et al (2015) An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database. Clin Exp Rheumatol 33(4 Suppl 91):S47–S54PubMed
55.
Zurück zum Zitat Mihai C, Landewe R, van der Heijde D, Walker UA, Constantin PI, Gherghe AM et al (2016) Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis Ann Rheum Dis 75:681–686PubMedCrossRef Mihai C, Landewe R, van der Heijde D, Walker UA, Constantin PI, Gherghe AM et al (2016) Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis Ann Rheum Dis 75:681–686PubMedCrossRef
56.
Zurück zum Zitat Cutolo M, Sulli A, Secchi ME, Paolino S, Pizzorni C (2006) Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement? Rheumatology 45:43–46CrossRef Cutolo M, Sulli A, Secchi ME, Paolino S, Pizzorni C (2006) Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement? Rheumatology 45:43–46CrossRef
57.
Zurück zum Zitat Sebastiani M, Manfredi A, Colaci M, D’amico R, Malagoli V, Giuggioli D et al (2009) Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum 61:688–694PubMedCrossRef Sebastiani M, Manfredi A, Colaci M, D’amico R, Malagoli V, Giuggioli D et al (2009) Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum 61:688–694PubMedCrossRef
58.
Zurück zum Zitat Ruaro B, Sulli A, Smith V, Paolino S, Pizzorni C, Cutolo M (2015) Short-term follow-up of digital ulcers by laser speckle contrast analysis in systemic sclerosis patients. Microvasc Res 101:82–85PubMedCrossRef Ruaro B, Sulli A, Smith V, Paolino S, Pizzorni C, Cutolo M (2015) Short-term follow-up of digital ulcers by laser speckle contrast analysis in systemic sclerosis patients. Microvasc Res 101:82–85PubMedCrossRef
59.
Zurück zum Zitat Barbano B, Marra AM, Quarta S, Gigante A, Barilaro G, Gasperini ML, Rosato E (2016) In systemic sclerosis skin perfusion of hands is reduced and may predict the occurrence of new digital ulcers. Microvasc Res 110:1–4PubMedCrossRef Barbano B, Marra AM, Quarta S, Gigante A, Barilaro G, Gasperini ML, Rosato E (2016) In systemic sclerosis skin perfusion of hands is reduced and may predict the occurrence of new digital ulcers. Microvasc Res 110:1–4PubMedCrossRef
60.
Zurück zum Zitat Anderson ME, Moore TL, Lunt M, Herrick AL (2007) The ‘distal-dorsal difference’: a thermographic parameter by which to differentiate between primary and secondary Raynaud’s phenomenon. Rheumatology 46:533–538PubMedCrossRef Anderson ME, Moore TL, Lunt M, Herrick AL (2007) The ‘distal-dorsal difference’: a thermographic parameter by which to differentiate between primary and secondary Raynaud’s phenomenon. Rheumatology 46:533–538PubMedCrossRef
61.
Zurück zum Zitat Onishi S, Homma Y, Hasegawa H, Yasukawa M (2013) Multiple tumoral calcinosis in systemic sclerosis. Intern Med 52:2689PubMedCrossRef Onishi S, Homma Y, Hasegawa H, Yasukawa M (2013) Multiple tumoral calcinosis in systemic sclerosis. Intern Med 52:2689PubMedCrossRef
62.
Zurück zum Zitat Valenzuela A, Chung L (2015) Calcinosis: pathophysiology and management. Curr Opin Rheumatol 27:542–548PubMedCrossRef Valenzuela A, Chung L (2015) Calcinosis: pathophysiology and management. Curr Opin Rheumatol 27:542–548PubMedCrossRef
63.
Zurück zum Zitat Zimmermann AF, Pizzichini MM (2013) Update on etiopathogenesis of systemic sclerosis. Rev Bras Reumatol 53:516–524PubMedCrossRef Zimmermann AF, Pizzichini MM (2013) Update on etiopathogenesis of systemic sclerosis. Rev Bras Reumatol 53:516–524PubMedCrossRef
64.
65.
Zurück zum Zitat Ee HL, Tan SH (2005) Reticulate hyperpigmented scleroderma: a new pigmentary manifestation. Clin Exp Dermatol 30:131–133PubMedCrossRef Ee HL, Tan SH (2005) Reticulate hyperpigmented scleroderma: a new pigmentary manifestation. Clin Exp Dermatol 30:131–133PubMedCrossRef
66.
Zurück zum Zitat Ziemek J, Man A, Hinchcliff M, Varga J, Simms RW, Lafyatis R (2016) The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis. Rheumatology 55:911–917PubMedCrossRef Ziemek J, Man A, Hinchcliff M, Varga J, Simms RW, Lafyatis R (2016) The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis. Rheumatology 55:911–917PubMedCrossRef
68.
Zurück zum Zitat Rongioletti F, Gambini C, Micalizzi C, Pastorino A, Rebora A (1994) Mucin deposits in morphea and systemic scleroderma. Dermatology 189:157–158PubMedCrossRef Rongioletti F, Gambini C, Micalizzi C, Pastorino A, Rebora A (1994) Mucin deposits in morphea and systemic scleroderma. Dermatology 189:157–158PubMedCrossRef
69.
Zurück zum Zitat Fett N, Werth VP (2011) Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 64:217–228PubMedCrossRef Fett N, Werth VP (2011) Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 64:217–228PubMedCrossRef
70.
Zurück zum Zitat Kreuter A, Krieg T, Worm M et al (2009) AWMF guideline no. 013/066. Diagnosis and therapy of circumscribed scleroderma. J Dtsch Dermatol Ges 7:1–14 Kreuter A, Krieg T, Worm M et al (2009) AWMF guideline no. 013/066. Diagnosis and therapy of circumscribed scleroderma. J Dtsch Dermatol Ges 7:1–14
71.
Zurück zum Zitat Ho KT, Reveille JD (2003) The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 5:80–93PubMed Ho KT, Reveille JD (2003) The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 5:80–93PubMed
72.
Zurück zum Zitat Kelly A, Derk CT (2015) Anti-RNA polymerase III antibodies in systemic sclerosis. Open J Rheumatol Autoimmune Dis 5:81–86CrossRef Kelly A, Derk CT (2015) Anti-RNA polymerase III antibodies in systemic sclerosis. Open J Rheumatol Autoimmune Dis 5:81–86CrossRef
73.
Zurück zum Zitat Arkachaisri T, Fertig N, Pino S, Medsger TA Jr (2008) Serum autoantibodies and their clinical associations in patients with childhood- and adult-onset linear scleroderma. A single-center study. J Rheumatol 35:2439–2444PubMedCrossRef Arkachaisri T, Fertig N, Pino S, Medsger TA Jr (2008) Serum autoantibodies and their clinical associations in patients with childhood- and adult-onset linear scleroderma. A single-center study. J Rheumatol 35:2439–2444PubMedCrossRef
74.
Zurück zum Zitat Walker KM, Pope J, participating members of the Scleroderma Clinical Trials Consortium (SCTC), Canadian Scleroderma Research Group (CSRG) (2012) Treatment of systemic sclerosis complications: what to use when first-line treatment fails—a consensus of systemic sclerosis experts. Semin Arthritis Rheum 42:42–55PubMedCrossRef Walker KM, Pope J, participating members of the Scleroderma Clinical Trials Consortium (SCTC), Canadian Scleroderma Research Group (CSRG) (2012) Treatment of systemic sclerosis complications: what to use when first-line treatment fails—a consensus of systemic sclerosis experts. Semin Arthritis Rheum 42:42–55PubMedCrossRef
75.
Zurück zum Zitat Pope JE, Bellamy N, Seibold JR et al (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44:1351–1358PubMedCrossRef Pope JE, Bellamy N, Seibold JR et al (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44:1351–1358PubMedCrossRef
77.
Zurück zum Zitat Tashkin DP, Elashoff R, Clements PJ, the Scleroderma Lung Study Research Group (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666PubMedCrossRef Tashkin DP, Elashoff R, Clements PJ, the Scleroderma Lung Study Research Group (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666PubMedCrossRef
78.
Zurück zum Zitat Connolly KL, Griffith JL, McEvoy M, Lim HW (2015) Ultraviolet A1 phototherapy beyond morphea: experience in 83 patients. Photodermatol Photoimmunol Photomed 31:289–295PubMedCrossRef Connolly KL, Griffith JL, McEvoy M, Lim HW (2015) Ultraviolet A1 phototherapy beyond morphea: experience in 83 patients. Photodermatol Photoimmunol Photomed 31:289–295PubMedCrossRef
79.
Zurück zum Zitat Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR scleroderma trials and research group (EUSTAR). Ann Rheum Dis 68:620–628PubMedCrossRef Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR scleroderma trials and research group (EUSTAR). Ann Rheum Dis 68:620–628PubMedCrossRef
80.
Zurück zum Zitat Mouthon L, Bussone G, Berezné A, Noël LH, Guillevin L (2014) Scleroderma renal crisis. J Rheumatol 41:1040–1048PubMedCrossRef Mouthon L, Bussone G, Berezné A, Noël LH, Guillevin L (2014) Scleroderma renal crisis. J Rheumatol 41:1040–1048PubMedCrossRef
81.
Zurück zum Zitat Papp G, Horvath IF, Barath S et al (2012) Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. Clin Immunol 142:150–159PubMedCrossRef Papp G, Horvath IF, Barath S et al (2012) Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. Clin Immunol 142:150–159PubMedCrossRef
82.
Zurück zum Zitat Knobler R, Berlin G, Calzavara-Pinton P et al (2014) Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol 28:1–37PubMedCrossRef Knobler R, Berlin G, Calzavara-Pinton P et al (2014) Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol 28:1–37PubMedCrossRef
83.
Zurück zum Zitat Thompson AE, Shea B, Welch V, Fenlon D, Pope JE (2001) Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 44:1841–1847PubMedCrossRef Thompson AE, Shea B, Welch V, Fenlon D, Pope JE (2001) Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 44:1841–1847PubMedCrossRef
84.
Zurück zum Zitat Hughes M, Ong VH, Anderson ME et al (2015) Consensus best practice pathway of the UK scleroderma study group: digital vasculopathy in systemic sclerosis. Rheumatology 54:2015–2024PubMedCrossRef Hughes M, Ong VH, Anderson ME et al (2015) Consensus best practice pathway of the UK scleroderma study group: digital vasculopathy in systemic sclerosis. Rheumatology 54:2015–2024PubMedCrossRef
85.
Zurück zum Zitat Fries R, Shariat K, von Wilmowsky H, Bohm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985PubMed Fries R, Shariat K, von Wilmowsky H, Bohm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985PubMed
86.
Zurück zum Zitat Foti R, Visalli E, Amato G et al (2017) Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen. Rheumatol Int 37:245–249PubMedCrossRef Foti R, Visalli E, Amato G et al (2017) Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen. Rheumatol Int 37:245–249PubMedCrossRef
87.
Zurück zum Zitat Tingey T, Shu J, Smuczek J et al (2013) Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken) 65:1460–1471CrossRef Tingey T, Shu J, Smuczek J et al (2013) Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken) 65:1460–1471CrossRef
88.
Zurück zum Zitat De Cata A, Inglese M, Molinaro F et al (2016) Digital ulcers in scleroderma patients: a retrospective observational study. Int J Immunopathol Pharmacol 29:180–187PubMedCrossRef De Cata A, Inglese M, Molinaro F et al (2016) Digital ulcers in scleroderma patients: a retrospective observational study. Int J Immunopathol Pharmacol 29:180–187PubMedCrossRef
89.
Zurück zum Zitat Balin SJ, Wetter DA, Andersen LK, Davis MD (2012) Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996–2009. Arch Dermatol 148:455–462PubMedCrossRef Balin SJ, Wetter DA, Andersen LK, Davis MD (2012) Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996–2009. Arch Dermatol 148:455–462PubMedCrossRef
90.
Zurück zum Zitat Gutierrez A Jr, Wetter DA (2012) Calcinosis cutis in autoimmune connective tissue diseases. Dermatol Ther 25:195–206PubMedCrossRef Gutierrez A Jr, Wetter DA (2012) Calcinosis cutis in autoimmune connective tissue diseases. Dermatol Ther 25:195–206PubMedCrossRef
91.
Zurück zum Zitat Dinsdale G, Murray A, Moore T et al (2014) A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial. Rheumatology 53:1422–1430PubMedCrossRef Dinsdale G, Murray A, Moore T et al (2014) A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial. Rheumatology 53:1422–1430PubMedCrossRef
92.
Zurück zum Zitat Denton CP, Khanna D (2017) Systemic sclerosis. Autoimmun Rev 16:377–384CrossRef Denton CP, Khanna D (2017) Systemic sclerosis. Autoimmun Rev 16:377–384CrossRef
93.
Zurück zum Zitat Sanges S, Rivière S, Mekinian A et al (2017) Intravenous immunoglobulins in systemic sclerosis: data from a French nationwide cohort of 46 patients and review of the literature. Autoimmun Rev 16:377–384PubMedCrossRef Sanges S, Rivière S, Mekinian A et al (2017) Intravenous immunoglobulins in systemic sclerosis: data from a French nationwide cohort of 46 patients and review of the literature. Autoimmun Rev 16:377–384PubMedCrossRef
94.
Zurück zum Zitat Lee JJ, Pope JE (2016) Emerging drugs and therapeutics for systemic sclerosis. Expert Opin Emerg Drugs 21:421–430PubMedCrossRef Lee JJ, Pope JE (2016) Emerging drugs and therapeutics for systemic sclerosis. Expert Opin Emerg Drugs 21:421–430PubMedCrossRef
95.
Zurück zum Zitat Tyndall AJ, Bannert B, Vonk M et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809PubMedCrossRef Tyndall AJ, Bannert B, Vonk M et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809PubMedCrossRef
96.
Zurück zum Zitat Rubio-Rivas M, Royo C, Simeón CP, Corbella X, Fonollosa V (2014) Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 44:208–219PubMedCrossRef Rubio-Rivas M, Royo C, Simeón CP, Corbella X, Fonollosa V (2014) Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 44:208–219PubMedCrossRef
98.
Zurück zum Zitat Peterson LS, Nelson AM, Su WP, Mason T, O’Fallon WM, Gabriel SE (1997) The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol 24:73–80PubMed Peterson LS, Nelson AM, Su WP, Mason T, O’Fallon WM, Gabriel SE (1997) The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol 24:73–80PubMed
99.
Zurück zum Zitat Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG et al (2006) Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 45:614–620CrossRef Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG et al (2006) Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 45:614–620CrossRef
100.
Zurück zum Zitat Murray KJ, Laxer RM (2002) Scleroderma in children and adolescents. Rheum Dis Clin N Am 28:603–624CrossRef Murray KJ, Laxer RM (2002) Scleroderma in children and adolescents. Rheum Dis Clin N Am 28:603–624CrossRef
101.
Zurück zum Zitat Christen-Zaech S, Hakim MD, Afsar FS, Paller AS (2008) Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol 59:385–396PubMedCrossRef Christen-Zaech S, Hakim MD, Afsar FS, Paller AS (2008) Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol 59:385–396PubMedCrossRef
102.
Zurück zum Zitat Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT (2009) Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol 145:545–550PubMedPubMedCentralCrossRef Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT (2009) Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol 145:545–550PubMedPubMedCentralCrossRef
103.
Zurück zum Zitat Marzano AV, Menni S, Parodi A, Borghi A, Fuligni A, Fabbri P et al (2003) Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol 13:171–176PubMed Marzano AV, Menni S, Parodi A, Borghi A, Fuligni A, Fabbri P et al (2003) Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol 13:171–176PubMed
104.
Zurück zum Zitat Zulian F, Cuffaro G, Sperotto F (2013) Scleroderma in children: an update. Curr Opin Rheumatol 25:643–650PubMedCrossRef Zulian F, Cuffaro G, Sperotto F (2013) Scleroderma in children: an update. Curr Opin Rheumatol 25:643–650PubMedCrossRef
105.
Zurück zum Zitat Slobodin G, Rimar D (2017) Regulatory T cells in systemic sclerosis: a comprehensive review. Clin Rev Allergy Immunol 52:194–201PubMedCrossRef Slobodin G, Rimar D (2017) Regulatory T cells in systemic sclerosis: a comprehensive review. Clin Rev Allergy Immunol 52:194–201PubMedCrossRef
106.
Zurück zum Zitat Peterson LS, Nelson AM, Su WP (1995) Classification of morphea (localized scleroderma). Mayo Clin Proc 70:1068–1076PubMedCrossRef Peterson LS, Nelson AM, Su WP (1995) Classification of morphea (localized scleroderma). Mayo Clin Proc 70:1068–1076PubMedCrossRef
107.
Zurück zum Zitat Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J et al (2005) Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 52:2873–2881PubMedCrossRef Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J et al (2005) Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 52:2873–2881PubMedCrossRef
109.
Zurück zum Zitat Avancini J, Valente NY, Romiti R (2015) Generalized lenticular atrophoderma of Pasini and Pierini. Pediatr Dermatol 32:389–391PubMedCrossRef Avancini J, Valente NY, Romiti R (2015) Generalized lenticular atrophoderma of Pasini and Pierini. Pediatr Dermatol 32:389–391PubMedCrossRef
110.
Zurück zum Zitat Zheng Y, Zhang R, Kang D, Zhu W (2015) Atrophoderma of Pasini and Pierini in zosteriform distribution. G Ital Dermatol Venereol 150:753–755PubMed Zheng Y, Zhang R, Kang D, Zhu W (2015) Atrophoderma of Pasini and Pierini in zosteriform distribution. G Ital Dermatol Venereol 150:753–755PubMed
111.
Zurück zum Zitat Tas B, Sar M (2015) Linear atrophoderma of Moulin: a distinct entity or blaschko-linear variant of atrophoderma of Pasini and Pierini? G Ital Dermatol Venereol 150:636–638PubMed Tas B, Sar M (2015) Linear atrophoderma of Moulin: a distinct entity or blaschko-linear variant of atrophoderma of Pasini and Pierini? G Ital Dermatol Venereol 150:636–638PubMed
112.
Zurück zum Zitat Zahedi Niaki O, Sissons W, Nguyen VH, Zargham R, Jafarian F (2015) Linear atrophoderma of Moulin: an underrecognized entity. Pediatr Rheumatol Online J 13:39PubMedPubMedCentralCrossRef Zahedi Niaki O, Sissons W, Nguyen VH, Zargham R, Jafarian F (2015) Linear atrophoderma of Moulin: an underrecognized entity. Pediatr Rheumatol Online J 13:39PubMedPubMedCentralCrossRef
114.
Zurück zum Zitat Kobayashi KA, Lui H, Prendiville JS (1991) Solitary morphea profunda in a 5-year-old girl: case report and review of the literature. Pediatr Dermatol 8:292–295PubMedCrossRef Kobayashi KA, Lui H, Prendiville JS (1991) Solitary morphea profunda in a 5-year-old girl: case report and review of the literature. Pediatr Dermatol 8:292–295PubMedCrossRef
115.
Zurück zum Zitat Kirsner RS, Pardes JB, Falanga V (1993) Solitary fibrosing paraspinal plaque: solitary morphea profunda. Br J Dermatol 128:99–101PubMedCrossRef Kirsner RS, Pardes JB, Falanga V (1993) Solitary fibrosing paraspinal plaque: solitary morphea profunda. Br J Dermatol 128:99–101PubMedCrossRef
116.
Zurück zum Zitat Azad J, Dawn G, Shaffrali FC, Holmes SC, Barnetson RJ, Forsyth A (2004) Does solitary morphea profunda progress? Clin Exp Dermatol 29:25–27PubMedCrossRef Azad J, Dawn G, Shaffrali FC, Holmes SC, Barnetson RJ, Forsyth A (2004) Does solitary morphea profunda progress? Clin Exp Dermatol 29:25–27PubMedCrossRef
117.
Zurück zum Zitat Blaszczyk M, Krysicka-Janiger K, Jabłońska S (2000) Primary atrophic profound linear scleroderma. Dermatology 200:63–66PubMedCrossRef Blaszczyk M, Krysicka-Janiger K, Jabłońska S (2000) Primary atrophic profound linear scleroderma. Dermatology 200:63–66PubMedCrossRef
118.
Zurück zum Zitat Malandrini A, Dotti MT, Federico A (1997) Selective ipsilateral neuromuscular involvement in a case of facial and somatic hemiatrophy. Muscle Nerve 20:890–892PubMedCrossRef Malandrini A, Dotti MT, Federico A (1997) Selective ipsilateral neuromuscular involvement in a case of facial and somatic hemiatrophy. Muscle Nerve 20:890–892PubMedCrossRef
119.
Zurück zum Zitat Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM (2010) Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken) 62:213–218CrossRef Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM (2010) Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken) 62:213–218CrossRef
120.
Zurück zum Zitat Hatzis JA, Stratigos AJ, Dimopoulos JC, Tzermias CK, Orfanidou A, Bassioukas KC (1992) Linear scleroderma with severe leg deformity. Australas J Dermatol 33:155–157PubMedCrossRef Hatzis JA, Stratigos AJ, Dimopoulos JC, Tzermias CK, Orfanidou A, Bassioukas KC (1992) Linear scleroderma with severe leg deformity. Australas J Dermatol 33:155–157PubMedCrossRef
122.
Zurück zum Zitat Chiang KL, Chang KP, Wong TT, Hsu TR (2009) Linear scleroderma “en coup de sabre”: initial presentation as intractable partial seizures in a child. Pediatr Neonatol 50:294–298PubMedCrossRef Chiang KL, Chang KP, Wong TT, Hsu TR (2009) Linear scleroderma “en coup de sabre”: initial presentation as intractable partial seizures in a child. Pediatr Neonatol 50:294–298PubMedCrossRef
123.
Zurück zum Zitat Tollefson MM, Witman PM (2007) En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol 56:257–263PubMedCrossRef Tollefson MM, Witman PM (2007) En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol 56:257–263PubMedCrossRef
124.
Zurück zum Zitat Chung MH, Sum J, Morrell MJ, Horoupian DS (1995) Intracerebral involvement in scleroderma en coup de sabre: report of case with neuropathologic findings. Ann Neurol 37:679–681PubMedCrossRef Chung MH, Sum J, Morrell MJ, Horoupian DS (1995) Intracerebral involvement in scleroderma en coup de sabre: report of case with neuropathologic findings. Ann Neurol 37:679–681PubMedCrossRef
125.
Zurück zum Zitat Lüer W, Jöckel D, Henze T, Schipper HI (1990) Progressive inflammatory lesions of the brain parenchyma in localized scleroderma of the head. J Neurol 237:379–381PubMedCrossRef Lüer W, Jöckel D, Henze T, Schipper HI (1990) Progressive inflammatory lesions of the brain parenchyma in localized scleroderma of the head. J Neurol 237:379–381PubMedCrossRef
126.
Zurück zum Zitat Jappe U, Hölzle E, Ring J (1996) Parry Romberg syndrome. Review and new observations based on a case with unusual features. Hautarzt 47:599–603PubMedCrossRef Jappe U, Hölzle E, Ring J (1996) Parry Romberg syndrome. Review and new observations based on a case with unusual features. Hautarzt 47:599–603PubMedCrossRef
127.
Zurück zum Zitat Jablonska S, Blaszczyk M, Rosinska D (1998) Progressive facial hemiatrophy and sclero- derma en coup de sabre: clinical presentation and course as related to the onset in early childhood and young adults. Arch Argent Dermatol 48:125–128 Jablonska S, Blaszczyk M, Rosinska D (1998) Progressive facial hemiatrophy and sclero- derma en coup de sabre: clinical presentation and course as related to the onset in early childhood and young adults. Arch Argent Dermatol 48:125–128
128.
Zurück zum Zitat Lehmann TJA (1992) The Parry-Romberg syndrome of progressive facial hemiatrophy and linear scleroderma en coup de sabre. Mistaken diagnosis or overlaping conditions? J Rheumatol 19:844–845 Lehmann TJA (1992) The Parry-Romberg syndrome of progressive facial hemiatrophy and linear scleroderma en coup de sabre. Mistaken diagnosis or overlaping conditions? J Rheumatol 19:844–845
129.
Zurück zum Zitat DeFelipe J, Segura T, Arellano JI, Merchán A, DeFelipe-Oroquieta J, Martín P et al (2001) Neuropathological findings in a patient with epilepsy and the Parry-Romberg syndrome. Epilepsia 42:1198–1203PubMedCrossRef DeFelipe J, Segura T, Arellano JI, Merchán A, DeFelipe-Oroquieta J, Martín P et al (2001) Neuropathological findings in a patient with epilepsy and the Parry-Romberg syndrome. Epilepsia 42:1198–1203PubMedCrossRef
130.
Zurück zum Zitat Woolfenden AR, Tong DC, Norbash AM, Albers GW (1998) Progressive facial hemiatrophy: abnormality of intracranial vasculature. Neurology 50:1915–1917PubMedCrossRef Woolfenden AR, Tong DC, Norbash AM, Albers GW (1998) Progressive facial hemiatrophy: abnormality of intracranial vasculature. Neurology 50:1915–1917PubMedCrossRef
131.
Zurück zum Zitat Gambichler T, Kreuter A, Hoffmann K, Bechara FG, Altmeyer P, Jansen T (2001) Billateral linear scleroderma “en coup de sabre” associated with facial atrophy and neurological complications. BMC Dermatol 1:9PubMedPubMedCentralCrossRef Gambichler T, Kreuter A, Hoffmann K, Bechara FG, Altmeyer P, Jansen T (2001) Billateral linear scleroderma “en coup de sabre” associated with facial atrophy and neurological complications. BMC Dermatol 1:9PubMedPubMedCentralCrossRef
132.
Zurück zum Zitat Wartenberg R (1945) Progressive facial hemiatrophy. Arch Neurol Psychiatr 54:75–96CrossRef Wartenberg R (1945) Progressive facial hemiatrophy. Arch Neurol Psychiatr 54:75–96CrossRef
133.
Zurück zum Zitat Wolf HG, Ehrenclou AH (1927) Trophic disorders of central origin: report of a case of progressive facial hemiatrophy associated with a lipodistrophy and other metabolic derangements. JAMA 88:991–994CrossRef Wolf HG, Ehrenclou AH (1927) Trophic disorders of central origin: report of a case of progressive facial hemiatrophy associated with a lipodistrophy and other metabolic derangements. JAMA 88:991–994CrossRef
134.
Zurück zum Zitat Parry CH (1825) Collections from unpublished papers, vol 178. Underwood, London, p 47 Parry CH (1825) Collections from unpublished papers, vol 178. Underwood, London, p 47
135.
Zurück zum Zitat Blaszczyk M, Królicki L, Krasu M, Glinska O, Jablonska S (2003) Progressive facial hemi- atrophy: central nervous system involvement and relationship with scleroderma en coup de sabre. J Rheumatol 30:1997–2004PubMed Blaszczyk M, Królicki L, Krasu M, Glinska O, Jablonska S (2003) Progressive facial hemi- atrophy: central nervous system involvement and relationship with scleroderma en coup de sabre. J Rheumatol 30:1997–2004PubMed
136.
Zurück zum Zitat Blaszczyk M, Jablonska S (1999) Linear scleroderma en coup de sabre. Relationship with progressive facial hemiatrophy (PFH). Adv Exp Med Biol 455:101–104PubMedCrossRef Blaszczyk M, Jablonska S (1999) Linear scleroderma en coup de sabre. Relationship with progressive facial hemiatrophy (PFH). Adv Exp Med Biol 455:101–104PubMedCrossRef
137.
Zurück zum Zitat Sánchez-Pérez S, Escandell-González I, Pinazo-Canales MI, Jordá-Cuevas E (2017) Bullous morphea: description of a new case and discussion of etiologic and pathogenic factors in bulla formation. Actas Dermosifiliogr 108:75–76PubMedCrossRef Sánchez-Pérez S, Escandell-González I, Pinazo-Canales MI, Jordá-Cuevas E (2017) Bullous morphea: description of a new case and discussion of etiologic and pathogenic factors in bulla formation. Actas Dermosifiliogr 108:75–76PubMedCrossRef
138.
Zurück zum Zitat Fernández Flores A, Gatica Torres M, Tinoco Fragoso F, García Hidalgo F, García Hidalgo L, Monroy E et al (2015) Three cases of bullous morphea: histopathologic findings with implications regarding pathogenesis. J Cutan Pathol 42:144–149PubMedCrossRef Fernández Flores A, Gatica Torres M, Tinoco Fragoso F, García Hidalgo F, García Hidalgo L, Monroy E et al (2015) Three cases of bullous morphea: histopathologic findings with implications regarding pathogenesis. J Cutan Pathol 42:144–149PubMedCrossRef
139.
Zurück zum Zitat Martinez SB, Gargallo V, Romero FT, Martinez LA, Peralto JL, Martín RL (2016) Generalized morphea with development of bullous lesions at the site of surgical scars. J Dtsch Dermatol Ges 14:827–829 Martinez SB, Gargallo V, Romero FT, Martinez LA, Peralto JL, Martín RL (2016) Generalized morphea with development of bullous lesions at the site of surgical scars. J Dtsch Dermatol Ges 14:827–829
140.
Zurück zum Zitat Qu T, Fang K (2014) Bullous morphea arising at the site of a healed herpes zoster. J Dermatol 41:553–554PubMedCrossRef Qu T, Fang K (2014) Bullous morphea arising at the site of a healed herpes zoster. J Dermatol 41:553–554PubMedCrossRef
141.
Zurück zum Zitat Falanga V, Medsger TA Jr, Reichlin M (1987) Antinuclear and anti-single-stranded DNA antibodies in morphea and generalized morphea. Arch Dermatol 123:350–353PubMedCrossRef Falanga V, Medsger TA Jr, Reichlin M (1987) Antinuclear and anti-single-stranded DNA antibodies in morphea and generalized morphea. Arch Dermatol 123:350–353PubMedCrossRef
142.
Zurück zum Zitat Arkachaisri T, Pino S (2008) Localized scleroderma severity index and global assessments: a pilot study of outcome instruments. J Rheumatol 35:650–657PubMedCrossRef Arkachaisri T, Pino S (2008) Localized scleroderma severity index and global assessments: a pilot study of outcome instruments. J Rheumatol 35:650–657PubMedCrossRef
143.
Zurück zum Zitat Kreuter A, Krieg T, Worm M, Wenzel J, Moinzadeh P, Kuhn A, Aberer E, Scharffetter-Kochanek K, Horneff G, Reil E, Weberschock T, Hunzelmann N (2016) German guidelines for the diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges 14:199–216PubMedCrossRef Kreuter A, Krieg T, Worm M, Wenzel J, Moinzadeh P, Kuhn A, Aberer E, Scharffetter-Kochanek K, Horneff G, Reil E, Weberschock T, Hunzelmann N (2016) German guidelines for the diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges 14:199–216PubMedCrossRef
144.
Zurück zum Zitat Cunningham BB, Landells ID, Langman C et al (1998) Topical calcipotriolo for morphea/linear scleroderma. J Am Acad Dermatol 39:211–215PubMedCrossRef Cunningham BB, Landells ID, Langman C et al (1998) Topical calcipotriolo for morphea/linear scleroderma. J Am Acad Dermatol 39:211–215PubMedCrossRef
145.
Zurück zum Zitat Stefanaki C, Stefanaki K, Kontochristopoulos G et al (2008) Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study. J Dermatol 35:712–718PubMedCrossRef Stefanaki C, Stefanaki K, Kontochristopoulos G et al (2008) Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study. J Dermatol 35:712–718PubMedCrossRef
146.
Zurück zum Zitat Kroft EB, Groeneveld TJ, Seyger MM, de Jong EM (2009) Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol 10:181–187PubMedCrossRef Kroft EB, Groeneveld TJ, Seyger MM, de Jong EM (2009) Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol 10:181–187PubMedCrossRef
147.
Zurück zum Zitat Kroft EB, Creemers MC, van den Hoogen FH, Boezeman JB, de Jong EM (2009) Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study. Br J Dermatol 160:1075–1082PubMedCrossRef Kroft EB, Creemers MC, van den Hoogen FH, Boezeman JB, de Jong EM (2009) Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study. Br J Dermatol 160:1075–1082PubMedCrossRef
148.
Zurück zum Zitat Li SC, Torok KS, Pope E et al (2012) Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken) 64:1175–1185 Li SC, Torok KS, Pope E et al (2012) Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken) 64:1175–1185
149.
Zurück zum Zitat Mertens JS, Marsman D, van de Kerkhof PC, Hoppenreijs EP, Knaapen HK, Radstake TR, de Jong EM, Seyger MM (2016) Use of mycophenolate Mofetil in patients with severe localized scleroderma resistant or intolerant to methotrexate. Acta Derm Venereol 96:510–513PubMedCrossRef Mertens JS, Marsman D, van de Kerkhof PC, Hoppenreijs EP, Knaapen HK, Radstake TR, de Jong EM, Seyger MM (2016) Use of mycophenolate Mofetil in patients with severe localized scleroderma resistant or intolerant to methotrexate. Acta Derm Venereol 96:510–513PubMedCrossRef
150.
Zurück zum Zitat Joly P, Bamberger N, Crickx B, Belaich S (1994) Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol 130:663–664PubMedCrossRef Joly P, Bamberger N, Crickx B, Belaich S (1994) Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol 130:663–664PubMedCrossRef
151.
Zurück zum Zitat Wright NA, Mazori DR, Patel M, Merola JF, Femia AN, Vleugels RA (2016) Epidemiology and treatment of eosinophilic fasciitis: an analysis of 63 patients from 3 tertiary care centers. JAMA Dermatol 152:97–99PubMedCrossRef Wright NA, Mazori DR, Patel M, Merola JF, Femia AN, Vleugels RA (2016) Epidemiology and treatment of eosinophilic fasciitis: an analysis of 63 patients from 3 tertiary care centers. JAMA Dermatol 152:97–99PubMedCrossRef
152.
Zurück zum Zitat Rongioletti F (2006) Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease. Semin Cutan Med Surg 25:100–104PubMedCrossRef Rongioletti F (2006) Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease. Semin Cutan Med Surg 25:100–104PubMedCrossRef
153.
Zurück zum Zitat Rongioletti F, Merlo G, Cinotti E et al (2013) Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol 69:66PubMedCrossRef Rongioletti F, Merlo G, Cinotti E et al (2013) Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol 69:66PubMedCrossRef
154.
Zurück zum Zitat Kim JS, Werth VP (2011) Identification of specific chondroitin sulfate species in cutaneous autoimmune disease. J Histochem Cytochem 59:780–790PubMedPubMedCentralCrossRef Kim JS, Werth VP (2011) Identification of specific chondroitin sulfate species in cutaneous autoimmune disease. J Histochem Cytochem 59:780–790PubMedPubMedCentralCrossRef
155.
Zurück zum Zitat Rongioletti F, Cattarini G, Sottofattori E, Rebora A (2003) Granulomatous reaction after intradermal injections of hyaluronic acid gel. Arch Dermatol 139:815–816PubMedCrossRef Rongioletti F, Cattarini G, Sottofattori E, Rebora A (2003) Granulomatous reaction after intradermal injections of hyaluronic acid gel. Arch Dermatol 139:815–816PubMedCrossRef
157.
Zurück zum Zitat Rongioletti F, Merlo G, Carli C et al (2016) Histopathologic characteristics of scleromyxedema: a study of a series of 34 cases. J Am Acad Dermatol 74:1194–1200PubMedCrossRef Rongioletti F, Merlo G, Carli C et al (2016) Histopathologic characteristics of scleromyxedema: a study of a series of 34 cases. J Am Acad Dermatol 74:1194–1200PubMedCrossRef
158.
Zurück zum Zitat Rongioletti F, Cozzani E, Parodi A (2010) Scleromyxedema with an interstitial granulomatous-like pattern: a rare histologic variant mimicking granuloma annulare. J Cutan Pathol 37:1084–1087PubMedCrossRef Rongioletti F, Cozzani E, Parodi A (2010) Scleromyxedema with an interstitial granulomatous-like pattern: a rare histologic variant mimicking granuloma annulare. J Cutan Pathol 37:1084–1087PubMedCrossRef
159.
Zurück zum Zitat Bidier M, Zschoche C, Gholam P et al (2012) Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes. Acta Derm Venereol 92:408PubMedCrossRef Bidier M, Zschoche C, Gholam P et al (2012) Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes. Acta Derm Venereol 92:408PubMedCrossRef
161.
Zurück zum Zitat Blum M, Wigley FM, Hummers LK (2008) Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore) 87:10–20CrossRef Blum M, Wigley FM, Hummers LK (2008) Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore) 87:10–20CrossRef
162.
Zurück zum Zitat Rey JB, Luria RB (2009) Treatment of scleromyxedema and dermatoneuro syndrome with intravenous immunoglobulin. J Am Acad Dermatol 60:1037–1041PubMedCrossRef Rey JB, Luria RB (2009) Treatment of scleromyxedema and dermatoneuro syndrome with intravenous immunoglobulin. J Am Acad Dermatol 60:1037–1041PubMedCrossRef
163.
Zurück zum Zitat Bidier M, Zschoche C, Gholam P et al (2012) Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes. Acta Derm Venereol 92:408–409PubMedCrossRef Bidier M, Zschoche C, Gholam P et al (2012) Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes. Acta Derm Venereol 92:408–409PubMedCrossRef
164.
Zurück zum Zitat Sansbury JC, Cocuroccia B, Jorizzo JL et al (2004) Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol 51:126–131PubMedCrossRef Sansbury JC, Cocuroccia B, Jorizzo JL et al (2004) Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol 51:126–131PubMedCrossRef
165.
Zurück zum Zitat Efthimiou P, Blanco M (2008) Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. Semin Arthritis Rheum 38:188–194PubMedCrossRef Efthimiou P, Blanco M (2008) Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. Semin Arthritis Rheum 38:188–194PubMedCrossRef
166.
Zurück zum Zitat Bos R, de Waal EG, Kuiper H et al (2011) Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema. Rheumatology (Oxford) 50:1925–1926CrossRef Bos R, de Waal EG, Kuiper H et al (2011) Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema. Rheumatology (Oxford) 50:1925–1926CrossRef
167.
Zurück zum Zitat Cañueto J, Labrador J, Román C et al (2012) The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights. Eur J Haematol 88:450PubMedCrossRef Cañueto J, Labrador J, Román C et al (2012) The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights. Eur J Haematol 88:450PubMedCrossRef
168.
Zurück zum Zitat Horn KB, Horn MA, Swan J et al (2004) A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema. J Am Acad Dermatol 51:S120–S123PubMedCrossRef Horn KB, Horn MA, Swan J et al (2004) A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema. J Am Acad Dermatol 51:S120–S123PubMedCrossRef
169.
Zurück zum Zitat Rongioletti F, Kaiser F, Cinotti E et al (2015) Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients. J Eur Acad Dermatol Venereol 29:2399–2404PubMedCrossRef Rongioletti F, Kaiser F, Cinotti E et al (2015) Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients. J Eur Acad Dermatol Venereol 29:2399–2404PubMedCrossRef
170.
Zurück zum Zitat Beers WH, Ince A, Moore TL (2006) Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum 35:355–359PubMedCrossRef Beers WH, Ince A, Moore TL (2006) Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum 35:355–359PubMedCrossRef
171.
Zurück zum Zitat Lewerenz V, Ruzicka T (2007) Scleredema adultorum associated with type 2 diabetes mellitus: a report of three cases. J Eur Acad Dermatol Venereol 21:560–561PubMed Lewerenz V, Ruzicka T (2007) Scleredema adultorum associated with type 2 diabetes mellitus: a report of three cases. J Eur Acad Dermatol Venereol 21:560–561PubMed
172.
Zurück zum Zitat Varga J, Gotta S, Li L, Sollberg S, Di Leonardo M (1995) Scleredema adultorum: case report and demonstration of abnormal expression of extracellular matrix genes in skin fibroblasts in vivo and in vitro. Br J Dermatol 132:992–999PubMedCrossRef Varga J, Gotta S, Li L, Sollberg S, Di Leonardo M (1995) Scleredema adultorum: case report and demonstration of abnormal expression of extracellular matrix genes in skin fibroblasts in vivo and in vitro. Br J Dermatol 132:992–999PubMedCrossRef
173.
Zurück zum Zitat Ioannidou DI, Krasagakis K, Stefanidou MP et al (2001) Scleredema adultorum of Buschke presenting as periorbital edema: a diagnostic challenge. J Am Acad Dermatol 65:41–44 Ioannidou DI, Krasagakis K, Stefanidou MP et al (2001) Scleredema adultorum of Buschke presenting as periorbital edema: a diagnostic challenge. J Am Acad Dermatol 65:41–44
174.
Zurück zum Zitat Morais P, Almeida M, Santos P, Azevedo F (2011) Scleredema of Buschke following mycoplasma pneumoniae respiratory infection. Int J Dermatol 50:454–457PubMedCrossRef Morais P, Almeida M, Santos P, Azevedo F (2011) Scleredema of Buschke following mycoplasma pneumoniae respiratory infection. Int J Dermatol 50:454–457PubMedCrossRef
175.
Zurück zum Zitat Rongioletti F, Rebora A (2001) Cutaneous mucinoses: microscopic criteria for diagnosis. Am J Dermatopathol 23:257–267PubMedCrossRef Rongioletti F, Rebora A (2001) Cutaneous mucinoses: microscopic criteria for diagnosis. Am J Dermatopathol 23:257–267PubMedCrossRef
176.
Zurück zum Zitat Miyares FJ, Kuriakose R, Deleu DT, El-Wahad NA, Al-Hail H (2008) Scleredema diabeticorum with unusual presentation and fatal outcome. Indian J Dermatol 53:217–219PubMedPubMedCentralCrossRef Miyares FJ, Kuriakose R, Deleu DT, El-Wahad NA, Al-Hail H (2008) Scleredema diabeticorum with unusual presentation and fatal outcome. Indian J Dermatol 53:217–219PubMedPubMedCentralCrossRef
177.
Zurück zum Zitat Xiao T, Yang ZH, He CD, Chen HD (2007) Scleredema adultorum treated with narrow-band ultraviolet B phototherapy. J Dermatol 34:270–272PubMedCrossRef Xiao T, Yang ZH, He CD, Chen HD (2007) Scleredema adultorum treated with narrow-band ultraviolet B phototherapy. J Dermatol 34:270–272PubMedCrossRef
178.
Zurück zum Zitat Yüksek J, Sezer E, Köseoğlu D, Markoç F, Yıldız H (2010) Scleredema treated with broad-band ultraviolet a phototherapy plus colchicine. Photodermatol Photoimmunol Photomed 26:257–260PubMedCrossRef Yüksek J, Sezer E, Köseoğlu D, Markoç F, Yıldız H (2010) Scleredema treated with broad-band ultraviolet a phototherapy plus colchicine. Photodermatol Photoimmunol Photomed 26:257–260PubMedCrossRef
179.
Zurück zum Zitat Szturz P, Adam Z, Vašků V, Feit J, Krejčí M, Pour L, Hájek R, Mayer J (2013) Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment. Leuk Lymphoma 54:1324–1326PubMedCrossRef Szturz P, Adam Z, Vašků V, Feit J, Krejčí M, Pour L, Hájek R, Mayer J (2013) Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment. Leuk Lymphoma 54:1324–1326PubMedCrossRef
180.
Zurück zum Zitat Lee FY, Chiu HY, Chiu HC (2011) Treatment of acquired reactive perforating collagenosis with allopurinol incidentally improves scleredema diabeticorum. J Am Acad Dermatol 65:e115–e117PubMedCrossRef Lee FY, Chiu HY, Chiu HC (2011) Treatment of acquired reactive perforating collagenosis with allopurinol incidentally improves scleredema diabeticorum. J Am Acad Dermatol 65:e115–e117PubMedCrossRef
181.
Zurück zum Zitat Stables GI, Taylor PC, Highet AS (2000) Scleredema associated with paraproteinaemia treated by extracorporeal photopheresis. Br J Dermatol 142:781–783PubMedCrossRef Stables GI, Taylor PC, Highet AS (2000) Scleredema associated with paraproteinaemia treated by extracorporeal photopheresis. Br J Dermatol 142:781–783PubMedCrossRef
182.
Zurück zum Zitat Bowen AR, Smith L, Zone JJ (2003) Scleredema adultorum of Buschke treated with radiation. Arch Dematol 139:780–784CrossRef Bowen AR, Smith L, Zone JJ (2003) Scleredema adultorum of Buschke treated with radiation. Arch Dematol 139:780–784CrossRef
183.
Zurück zum Zitat Aichelburg MC, Loewe R, Schicher N, Sator PG, Karlhofer FM, Stingl G, Jalili A (2012) Successful treatment of poststreptococcal scleredema adultorum Buschke with intravenous immunoglobulins. Arch Dermatol 148:1126–1128PubMedCrossRef Aichelburg MC, Loewe R, Schicher N, Sator PG, Karlhofer FM, Stingl G, Jalili A (2012) Successful treatment of poststreptococcal scleredema adultorum Buschke with intravenous immunoglobulins. Arch Dermatol 148:1126–1128PubMedCrossRef
184.
Zurück zum Zitat Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000–1001PubMedCrossRef Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000–1001PubMedCrossRef
185.
Zurück zum Zitat Girardi M, Kay J, Elston DM, LeBoit PE, Abu-Alfa A, Cowper SE (2011) Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 65:1095–1106.e7PubMedCrossRef Girardi M, Kay J, Elston DM, LeBoit PE, Abu-Alfa A, Cowper SE (2011) Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 65:1095–1106.e7PubMedCrossRef
186.
Zurück zum Zitat Knopp EA, Cowper SE (2008) Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 21:123–128PubMedCrossRef Knopp EA, Cowper SE (2008) Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 21:123–128PubMedCrossRef
187.
Zurück zum Zitat Thomsen HS, Marckmann P (2008) Extracellular Gd-CA: differences in prevalence of NSF. Eur J Radiol 66:180–183PubMedCrossRef Thomsen HS, Marckmann P (2008) Extracellular Gd-CA: differences in prevalence of NSF. Eur J Radiol 66:180–183PubMedCrossRef
188.
Zurück zum Zitat Thomsen HS, Morcos SK, Almen T et al (2013) Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR contrast medium safety committee guidelines. Eur Radiol 23:307–318PubMedCrossRef Thomsen HS, Morcos SK, Almen T et al (2013) Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR contrast medium safety committee guidelines. Eur Radiol 23:307–318PubMedCrossRef
189.
Zurück zum Zitat Jan F, Segal JM, Dyer J, LeBoit P, Siegfried E, Frieden IJ (2003) Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 143:678–681PubMedCrossRef Jan F, Segal JM, Dyer J, LeBoit P, Siegfried E, Frieden IJ (2003) Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 143:678–681PubMedCrossRef
190.
Zurück zum Zitat Perazella MA, Rodby RA (2007) Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial 20:179–185PubMedCrossRef Perazella MA, Rodby RA (2007) Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial 20:179–185PubMedCrossRef
191.
Zurück zum Zitat Newton BB, Jimenez SA (2009) Mechanism of NSF: new evidence challenging the prevailing theory. J Magn Reson Imaging 30:1277–1283PubMedCrossRef Newton BB, Jimenez SA (2009) Mechanism of NSF: new evidence challenging the prevailing theory. J Magn Reson Imaging 30:1277–1283PubMedCrossRef
192.
Zurück zum Zitat Cowper SE (2003) Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 15:785–790PubMedCrossRef Cowper SE (2003) Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 15:785–790PubMedCrossRef
193.
Zurück zum Zitat Larson KN, Gagnon AL, Darling MD, Patterson JW, Cropley TG (2015) Nephrogenic systemic fibrosis manifesting a decade after exposure to gadolinium. JAMA Dermatol 151:1117–1120PubMedCrossRef Larson KN, Gagnon AL, Darling MD, Patterson JW, Cropley TG (2015) Nephrogenic systemic fibrosis manifesting a decade after exposure to gadolinium. JAMA Dermatol 151:1117–1120PubMedCrossRef
194.
195.
Zurück zum Zitat Swaminathan S, High WA, Ranville J, Horn TD, Hiatt K, Thomas M et al (2008) Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 73:1413–1418PubMedCrossRef Swaminathan S, High WA, Ranville J, Horn TD, Hiatt K, Thomas M et al (2008) Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 73:1413–1418PubMedCrossRef
196.
Zurück zum Zitat High WA, Ayers RA, Chandler J et al (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:21PubMedCrossRef High WA, Ayers RA, Chandler J et al (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:21PubMedCrossRef
198.
Zurück zum Zitat Bhawan J, Perez-Chua TA, Goldberg L (2013) Sclerotic bodies beyond nephrogenic systemic fibrosis. J Cutan Pathol 40:812–817PubMedCrossRef Bhawan J, Perez-Chua TA, Goldberg L (2013) Sclerotic bodies beyond nephrogenic systemic fibrosis. J Cutan Pathol 40:812–817PubMedCrossRef
199.
Zurück zum Zitat Boyd AS, Zic JA, Abraham JL (2007) Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56:27PubMedCrossRef Boyd AS, Zic JA, Abraham JL (2007) Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56:27PubMedCrossRef
200.
Zurück zum Zitat High WA, Ayers RA, Cowper SE (2007) Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:710PubMedCrossRef High WA, Ayers RA, Cowper SE (2007) Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:710PubMedCrossRef
201.
Zurück zum Zitat Igreja AC, Mesquita Kde C, Cowper SE, Costa IM (2012) Nephrogenic systemic fibrosis: concepts and perspective. An Bras Dermatol 87:597–607PubMedCrossRef Igreja AC, Mesquita Kde C, Cowper SE, Costa IM (2012) Nephrogenic systemic fibrosis: concepts and perspective. An Bras Dermatol 87:597–607PubMedCrossRef
202.
Zurück zum Zitat Elmholdt TR, Buus NH, Ramsing M, Olesen AB (2013) Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial. J Eur Acad Dermatol Venereol 27:779–784PubMedCrossRef Elmholdt TR, Buus NH, Ramsing M, Olesen AB (2013) Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial. J Eur Acad Dermatol Venereol 27:779–784PubMedCrossRef
203.
Zurück zum Zitat Mendoza FA, Artlett CM, Sandorfi N et al (2006) Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35:238PubMedPubMedCentralCrossRef Mendoza FA, Artlett CM, Sandorfi N et al (2006) Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35:238PubMedPubMedCentralCrossRef
204.
Zurück zum Zitat Cuffy MC, Singh M, Formica R et al (2011) Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant 26:1099–1101PubMedCrossRef Cuffy MC, Singh M, Formica R et al (2011) Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant 26:1099–1101PubMedCrossRef
206.
Zurück zum Zitat Shulman LE (1974) Diffuse fasciite with hypergammaglobulinemia and eosinophilia: a new syndrome? J Rheumatol 1:46–49 Shulman LE (1974) Diffuse fasciite with hypergammaglobulinemia and eosinophilia: a new syndrome? J Rheumatol 1:46–49
207.
Zurück zum Zitat Lebeaux D, Sène D (2012) Eosinophilic fasciitis (Shulman disease). Best Pract Res Clin Rheumatol 26:449–458PubMedCrossRef Lebeaux D, Sène D (2012) Eosinophilic fasciitis (Shulman disease). Best Pract Res Clin Rheumatol 26:449–458PubMedCrossRef
208.
209.
Zurück zum Zitat Sène D (2015) Eosinophilic fasciitis (Shulman’s disease): diagnostic and therapeutic review. Rev Med Interne 36:738–745PubMedCrossRef Sène D (2015) Eosinophilic fasciitis (Shulman’s disease): diagnostic and therapeutic review. Rev Med Interne 36:738–745PubMedCrossRef
210.
Zurück zum Zitat Pinal-Fernandez I, Selva-O’ Callaghan A, Grau JM (2014) Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev 13:379–3824PubMedCrossRef Pinal-Fernandez I, Selva-O’ Callaghan A, Grau JM (2014) Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev 13:379–3824PubMedCrossRef
211.
Zurück zum Zitat Endo Y, Tamura A, Matsushima Y, Iwasaki T, Hasegawa M, Nagai Y, Ishikawa O (2007) Eosinophilic fasciitis: report of two cases and a systematic review of the literature dealing with clinical variables that predict outcome. Clin Rheumatol 26:1445–1451PubMedCrossRef Endo Y, Tamura A, Matsushima Y, Iwasaki T, Hasegawa M, Nagai Y, Ishikawa O (2007) Eosinophilic fasciitis: report of two cases and a systematic review of the literature dealing with clinical variables that predict outcome. Clin Rheumatol 26:1445–1451PubMedCrossRef
212.
Zurück zum Zitat Bischoff L, Derk CT (2008) Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol 47:29–35PubMedCrossRef Bischoff L, Derk CT (2008) Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol 47:29–35PubMedCrossRef
213.
Zurück zum Zitat Toquet C, Hamidou MA, Renaudin K, Jarry A, Foulc P, Barbarot S, Laboisse C, Mussini JM (2003) In situ immunophenotype of the inflammatory infiltrate in eosinophilic fasciitis. J Rheumatol 30:1811–1815PubMed Toquet C, Hamidou MA, Renaudin K, Jarry A, Foulc P, Barbarot S, Laboisse C, Mussini JM (2003) In situ immunophenotype of the inflammatory infiltrate in eosinophilic fasciitis. J Rheumatol 30:1811–1815PubMed
214.
Zurück zum Zitat Asano Y, Ihn H, Jinnin M, Tamaki Z, Tamaki K, Sato S (2014) Serum levels of matrix metalloproteinase-13 in patients with eosinophilic fasciitis. J Dermatol 41:746–748PubMedCrossRef Asano Y, Ihn H, Jinnin M, Tamaki Z, Tamaki K, Sato S (2014) Serum levels of matrix metalloproteinase-13 in patients with eosinophilic fasciitis. J Dermatol 41:746–748PubMedCrossRef
215.
Zurück zum Zitat Daniel RS, Lavery S, Maize JC Jr, Brown AN, Bolster MB (2009) Unilateral eosinophilic fasciitis: an under-recognized subtype? J Clin Rheumatol 15:247–249PubMedCrossRef Daniel RS, Lavery S, Maize JC Jr, Brown AN, Bolster MB (2009) Unilateral eosinophilic fasciitis: an under-recognized subtype? J Clin Rheumatol 15:247–249PubMedCrossRef
216.
Zurück zum Zitat Patterson J (2016) Disorders of collagen. In: Weedon’s skin pathology, 4th edn. Elsevier, pp 348–379 Patterson J (2016) Disorders of collagen. In: Weedon’s skin pathology, 4th edn. Elsevier, pp 348–379
217.
Zurück zum Zitat Nashel J, Steen V (2015) The use of an elevated aldolase in diagnosing and managing eosinophilic fasciitis. Clin Rheumatol 34:1481–1484PubMedCrossRef Nashel J, Steen V (2015) The use of an elevated aldolase in diagnosing and managing eosinophilic fasciitis. Clin Rheumatol 34:1481–1484PubMedCrossRef
218.
Zurück zum Zitat Jinnin M, Ihn H, Yamane K, Asano Y, Yazawa N, Tamaki K (2004) Serum levels of tissue inhibitor of metalloproteinase-1 and 2 in patients with eosinophilic fasciitis. Br J Dermatol 151:407–412PubMedCrossRef Jinnin M, Ihn H, Yamane K, Asano Y, Yazawa N, Tamaki K (2004) Serum levels of tissue inhibitor of metalloproteinase-1 and 2 in patients with eosinophilic fasciitis. Br J Dermatol 151:407–412PubMedCrossRef
219.
Zurück zum Zitat Dybowski F, Neuen-Jacob E, Braun J (2008) Eosinophilic fasciitis and myositis: use of imaging modalities for diagnosis and monitoring. Ann Rheum Dis 67:572–574PubMedCrossRef Dybowski F, Neuen-Jacob E, Braun J (2008) Eosinophilic fasciitis and myositis: use of imaging modalities for diagnosis and monitoring. Ann Rheum Dis 67:572–574PubMedCrossRef
220.
Zurück zum Zitat Kurimoto R, Ikeda K, Nakagomi D, Nakajima H (2016) Eosinophilic fasciitis illustrated by [(18)F] FDG-PET/CT. Intern Med 55:2321–2322PubMedCrossRef Kurimoto R, Ikeda K, Nakagomi D, Nakajima H (2016) Eosinophilic fasciitis illustrated by [(18)F] FDG-PET/CT. Intern Med 55:2321–2322PubMedCrossRef
221.
Zurück zum Zitat Mondal S, Goswami RP, Sinha D, Ghosh A (2015) Ultrasound is a useful adjunct in diagnosis of eosinophilic fasciitis. Rheumatology 54:2041PubMedCrossRef Mondal S, Goswami RP, Sinha D, Ghosh A (2015) Ultrasound is a useful adjunct in diagnosis of eosinophilic fasciitis. Rheumatology 54:2041PubMedCrossRef
222.
Zurück zum Zitat Oza VS, Walsh R, North J, Berger TG, Murase JE (2016) Treatment of eosinophilic fasciitis with Sirolimus. JAMA Dermatol 152:488–490PubMedCrossRef Oza VS, Walsh R, North J, Berger TG, Murase JE (2016) Treatment of eosinophilic fasciitis with Sirolimus. JAMA Dermatol 152:488–490PubMedCrossRef
223.
Zurück zum Zitat Mertens JS, Zweers MC, Kievit W, Knaapen HK, Gerritsen M, Radstake TR, van den Hoogen FH, Creemers MC, de Jong EM (2016) High-dose intravenous pulse methotrexate in patients with eosinophilic fasciitis. JAMA Dermatol 152:1262–1265PubMedCrossRef Mertens JS, Zweers MC, Kievit W, Knaapen HK, Gerritsen M, Radstake TR, van den Hoogen FH, Creemers MC, de Jong EM (2016) High-dose intravenous pulse methotrexate in patients with eosinophilic fasciitis. JAMA Dermatol 152:1262–1265PubMedCrossRef
224.
Zurück zum Zitat Kroft EB, Berkhof NJ, van de Kerkhof PC, Gerritsen RM, de Jong EM (2008) Ultraviolet a phototherapy for sclerotic skin diseases: a systematic review. J Am Acad Dermatol 59:1017–1030PubMedCrossRef Kroft EB, Berkhof NJ, van de Kerkhof PC, Gerritsen RM, de Jong EM (2008) Ultraviolet a phototherapy for sclerotic skin diseases: a systematic review. J Am Acad Dermatol 59:1017–1030PubMedCrossRef
225.
Zurück zum Zitat Romano C, Rubegni P, De Aloe G, Stanghellini E, D’Ascenzo G, Andreassi L, Fimiani M (2003) Extracorporeal photochemotherapy in the treatment of eosinophilic fasciitis. J Eur Acad Dermatol Venereol 17:10–13PubMedCrossRef Romano C, Rubegni P, De Aloe G, Stanghellini E, D’Ascenzo G, Andreassi L, Fimiani M (2003) Extracorporeal photochemotherapy in the treatment of eosinophilic fasciitis. J Eur Acad Dermatol Venereol 17:10–13PubMedCrossRef
226.
Zurück zum Zitat Hymes SR, Alousi AM, Cowen EW (2012) Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol 66:515.e1–515.18CrossRef Hymes SR, Alousi AM, Cowen EW (2012) Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol 66:515.e1–515.18CrossRef
227.
Zurück zum Zitat Chosidow O, Bagot M, Vernant JP, Roujeau JC, Cordonnier C, Kuentz M, Wechsler J, André C, Touraine R, Revuz J (1992) Sclerodermatous chronic graft-versus-host disease. Analysis of seven cases. J Am Acad Dermatol 26:49–55PubMedCrossRef Chosidow O, Bagot M, Vernant JP, Roujeau JC, Cordonnier C, Kuentz M, Wechsler J, André C, Touraine R, Revuz J (1992) Sclerodermatous chronic graft-versus-host disease. Analysis of seven cases. J Am Acad Dermatol 26:49–55PubMedCrossRef
228.
Zurück zum Zitat Zhang J, Chen F, Ueki T, Date H (2015) Imatinib for sclerodermatous graft-versus-host disease in lung transplantation. Interact Cardiovasc Thorac Surg 21:260–262PubMedCrossRef Zhang J, Chen F, Ueki T, Date H (2015) Imatinib for sclerodermatous graft-versus-host disease in lung transplantation. Interact Cardiovasc Thorac Surg 21:260–262PubMedCrossRef
229.
Zurück zum Zitat Lazzeri L, Tripo L, Pescitelli L, Ricceri F, Prignano F (2016) A pediatric case of Sclerodermatous graft-versus-host disease responsive to ultraviolet A1 phototherapy. Pediatr Dermatol 33:e99–102PubMedCrossRef Lazzeri L, Tripo L, Pescitelli L, Ricceri F, Prignano F (2016) A pediatric case of Sclerodermatous graft-versus-host disease responsive to ultraviolet A1 phototherapy. Pediatr Dermatol 33:e99–102PubMedCrossRef
230.
Zurück zum Zitat Bisaccia E, Palangio M, Gonzalez J (2011) Long-term extracorporeal photochemotherapy in a pediatric patient with refractory sclerodermatous chronic graft-versus-host disease. Transfus Apher Sci 45:187–190PubMedCrossRef Bisaccia E, Palangio M, Gonzalez J (2011) Long-term extracorporeal photochemotherapy in a pediatric patient with refractory sclerodermatous chronic graft-versus-host disease. Transfus Apher Sci 45:187–190PubMedCrossRef
231.
Zurück zum Zitat Bell SA, Faust H, Mittermüller J, Kolb HJ, Meurer M (1996) Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association. Br J Dermatol 134:848–854PubMedCrossRef Bell SA, Faust H, Mittermüller J, Kolb HJ, Meurer M (1996) Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association. Br J Dermatol 134:848–854PubMedCrossRef
232.
Zurück zum Zitat Higman MA, Vogelsang GB (2004) Chronic graft versus host disease. Br J Haematol 125:435–454PubMedCrossRef Higman MA, Vogelsang GB (2004) Chronic graft versus host disease. Br J Haematol 125:435–454PubMedCrossRef
233.
Zurück zum Zitat White JM, Devereux S, Pagliuca A, Salisbury JR, du Vivier AW, Creamer D (2006) Koebnerizing sclerodermatous graft-versus-host disease caused by donor lymphocyte infusion and interferon-alpha. Br J Dermatol 155:621–623PubMedCrossRef White JM, Devereux S, Pagliuca A, Salisbury JR, du Vivier AW, Creamer D (2006) Koebnerizing sclerodermatous graft-versus-host disease caused by donor lymphocyte infusion and interferon-alpha. Br J Dermatol 155:621–623PubMedCrossRef
234.
Zurück zum Zitat Delaney TA, Morehouse C, Brohawn PZ, Groves C, Colonna M, Yao Y, Sanjuan M, Coyle AJ (2016) Type I IFNs regulate inflammation, vasculopathy, and fibrosis in chronic cutaneous graft-versus-host disease. J Immunol 197:42–50PubMedCrossRef Delaney TA, Morehouse C, Brohawn PZ, Groves C, Colonna M, Yao Y, Sanjuan M, Coyle AJ (2016) Type I IFNs regulate inflammation, vasculopathy, and fibrosis in chronic cutaneous graft-versus-host disease. J Immunol 197:42–50PubMedCrossRef
236.
Zurück zum Zitat Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A (2009) Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 15:1005–1013PubMedCrossRef Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A (2009) Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 15:1005–1013PubMedCrossRef
237.
Zurück zum Zitat White JM, Creamer D, du Vivier AW, Pagliuca A, Ho AY, Devereux S, Salisbury JR, Mufti GJ (2007) Sclerodermatous graft-versus-host disease: clinical spectrum and therapeutic challenges. Br J Dermatol 156:1032–1038PubMedCrossRef White JM, Creamer D, du Vivier AW, Pagliuca A, Ho AY, Devereux S, Salisbury JR, Mufti GJ (2007) Sclerodermatous graft-versus-host disease: clinical spectrum and therapeutic challenges. Br J Dermatol 156:1032–1038PubMedCrossRef
238.
Zurück zum Zitat Peñas PF, Jones-Caballero M, Aragués M, Fernández-Herrera J, Fraga J, Garcia-Diez A (2002) Sclerodermatous graft-vs-host disease. Clinical and pathological study of 17 patients. Arch Dermatol 138:924–934PubMedCrossRef Peñas PF, Jones-Caballero M, Aragués M, Fernández-Herrera J, Fraga J, Garcia-Diez A (2002) Sclerodermatous graft-vs-host disease. Clinical and pathological study of 17 patients. Arch Dermatol 138:924–934PubMedCrossRef
239.
Zurück zum Zitat Schaffer JV, McNiff JM, Seropian S, Cooper DL, Bolognia JL (2005) Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: expanding the sclerodermoid spectrum. J Am Acad Dermatol 53:591–601PubMedCrossRef Schaffer JV, McNiff JM, Seropian S, Cooper DL, Bolognia JL (2005) Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: expanding the sclerodermoid spectrum. J Am Acad Dermatol 53:591–601PubMedCrossRef
240.
Zurück zum Zitat Jachiet M, de Masson A, Peffault de Latour R, Rybojad M, Robin M, Bourhis JH, Xhaard A, Dhedin N, Sicre de Fontbrune F, Suarez F, Barete S, Parquet N, Nguyen S, Ades L, Rubio MT, Wittnebel S, Bagot M, Socié G, Bouaziz JD (2014) Skin ulcers related to chronic graft-versus-host disease: clinical findings and associated morbidity. Br J Dermatol 171:63–68PubMedCrossRef Jachiet M, de Masson A, Peffault de Latour R, Rybojad M, Robin M, Bourhis JH, Xhaard A, Dhedin N, Sicre de Fontbrune F, Suarez F, Barete S, Parquet N, Nguyen S, Ades L, Rubio MT, Wittnebel S, Bagot M, Socié G, Bouaziz JD (2014) Skin ulcers related to chronic graft-versus-host disease: clinical findings and associated morbidity. Br J Dermatol 171:63–68PubMedCrossRef
241.
Zurück zum Zitat Akay BN, Sanli H, Topcuoglu P, Arat M, Akyol A (2010) Nailfold capillary abnormalities are prevalent in sclerodermoid graft-versus-host disease and readily detected with dermatoscopy. Br J Dermatol 162:1076–1082PubMedCrossRef Akay BN, Sanli H, Topcuoglu P, Arat M, Akyol A (2010) Nailfold capillary abnormalities are prevalent in sclerodermoid graft-versus-host disease and readily detected with dermatoscopy. Br J Dermatol 162:1076–1082PubMedCrossRef
242.
Zurück zum Zitat Man J, Man J, Kalisiak M, Birchall IW, Salopek TG (2010) Chronic cutaneous graft-versus-host disease manifesting as calcinosis cutis universalis on a background of widespread sclerodermatoid changes. J Cutan Med Surg 14:249–253PubMedCrossRef Man J, Man J, Kalisiak M, Birchall IW, Salopek TG (2010) Chronic cutaneous graft-versus-host disease manifesting as calcinosis cutis universalis on a background of widespread sclerodermatoid changes. J Cutan Med Surg 14:249–253PubMedCrossRef
243.
Zurück zum Zitat Osmola-Mańkowska A, Silny W, Dańczak-Pazdrowska A, Polańska A, Olek-Hrab K, Sadowska-Przytocka A, Żaba R, Jenerowicz D (2013) Assessment of chronic sclerodermoid graft-versus-host disease patients, using 20 MHz high-frequency ultrasonography and cutometer methods. Skin Res Technol 19:e417–e422PubMedCrossRef Osmola-Mańkowska A, Silny W, Dańczak-Pazdrowska A, Polańska A, Olek-Hrab K, Sadowska-Przytocka A, Żaba R, Jenerowicz D (2013) Assessment of chronic sclerodermoid graft-versus-host disease patients, using 20 MHz high-frequency ultrasonography and cutometer methods. Skin Res Technol 19:e417–e422PubMedCrossRef
244.
Zurück zum Zitat Carcagnì MR, De Aloe G, D’Ascenzo G, Rubegni P, Fimiani M (2008) Extracorporeal photopheresis in graft-versus-host disease. J Dtsch Dermatol Ges 6:451–457PubMedCrossRef Carcagnì MR, De Aloe G, D’Ascenzo G, Rubegni P, Fimiani M (2008) Extracorporeal photopheresis in graft-versus-host disease. J Dtsch Dermatol Ges 6:451–457PubMedCrossRef
245.
Zurück zum Zitat Calzavara Pinton P, Porta F, Izzi T, Venturini M, Capezzera R, Zane C, Notarangelo LD (2003) Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease. Haematologica 88:1169–1175PubMed Calzavara Pinton P, Porta F, Izzi T, Venturini M, Capezzera R, Zane C, Notarangelo LD (2003) Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease. Haematologica 88:1169–1175PubMed
246.
Zurück zum Zitat Lazar J, Poonawalla T, Teng JM (2011) A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy. Pediatr Dermatol 28:172–175PubMedCrossRef Lazar J, Poonawalla T, Teng JM (2011) A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy. Pediatr Dermatol 28:172–175PubMedCrossRef
247.
Zurück zum Zitat Pines M, Snyder D, Yarkoni S, Nagler A (2003) Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 9:417–425PubMedCrossRef Pines M, Snyder D, Yarkoni S, Nagler A (2003) Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 9:417–425PubMedCrossRef
249.
Zurück zum Zitat Amezyane T, Abouzahir A, Fatihi J, Sekkach Y, Mahassin F, Sedrati O, Ghafir D, Ohayon V (2010) A sclerodermiform porphyria cutanea tarda. Intern Med 49:205–206PubMedCrossRef Amezyane T, Abouzahir A, Fatihi J, Sekkach Y, Mahassin F, Sedrati O, Ghafir D, Ohayon V (2010) A sclerodermiform porphyria cutanea tarda. Intern Med 49:205–206PubMedCrossRef
250.
Zurück zum Zitat Kranzelbinder B, Wiednig M, El-Shabrawi-Caelen L, Aberer W, Aberer E (2015) Sclerodermiform porphyria cutanea tarda after torasemide. Eur J Dermatol 25:484–485PubMed Kranzelbinder B, Wiednig M, El-Shabrawi-Caelen L, Aberer W, Aberer E (2015) Sclerodermiform porphyria cutanea tarda after torasemide. Eur J Dermatol 25:484–485PubMed
251.
Zurück zum Zitat Wallaeys E, Thierling U, Lang E, Neumann NJ, Frank J (2014) Porphyria cutanea tarda with sclerodermatous changes and hemochromatosis. Hautarzt 65:272–274PubMedCrossRef Wallaeys E, Thierling U, Lang E, Neumann NJ, Frank J (2014) Porphyria cutanea tarda with sclerodermatous changes and hemochromatosis. Hautarzt 65:272–274PubMedCrossRef
252.
Zurück zum Zitat Lim HW (1989) Mechanisms of phototoxicity in porphyria cutanea tarda and erythropoietic protoporphyria. Immunol Ser 46:671–685PubMed Lim HW (1989) Mechanisms of phototoxicity in porphyria cutanea tarda and erythropoietic protoporphyria. Immunol Ser 46:671–685PubMed
253.
Zurück zum Zitat Torinuki W, Kudoh K, Tagami H (1989) Increased mast cell numbers in the sclerotic skin of Porphyria Cutanea Tarda. Dermatologica 178:75–78PubMedCrossRef Torinuki W, Kudoh K, Tagami H (1989) Increased mast cell numbers in the sclerotic skin of Porphyria Cutanea Tarda. Dermatologica 178:75–78PubMedCrossRef
254.
Zurück zum Zitat Thomas CL, Badminton MN, Rendall JR, Anstey AV (2008) Sclerodermatous changes of face, neck and scalp associated with familial porphyria cutanea tarda. Clin Exp Dermatol 33:422–442PubMedCrossRef Thomas CL, Badminton MN, Rendall JR, Anstey AV (2008) Sclerodermatous changes of face, neck and scalp associated with familial porphyria cutanea tarda. Clin Exp Dermatol 33:422–442PubMedCrossRef
255.
Zurück zum Zitat Khayat R, Dupuy A, Pansé I, Bagot M, Cordoliani F (2013) Sclerodermatous changes in porphyria cutanea tarda: six cases. Ann Dermatol Venereol 140:589–597PubMedCrossRef Khayat R, Dupuy A, Pansé I, Bagot M, Cordoliani F (2013) Sclerodermatous changes in porphyria cutanea tarda: six cases. Ann Dermatol Venereol 140:589–597PubMedCrossRef
256.
Zurück zum Zitat Zemtsov R, Zemtsov A (2010) Porphyria cutanea tarda presenting as scleroderma. Cutis 85:203–205PubMed Zemtsov R, Zemtsov A (2010) Porphyria cutanea tarda presenting as scleroderma. Cutis 85:203–205PubMed
257.
Zurück zum Zitat Bulaj ZJ, Phillips JD, Ajioka RS, Franklin MR, Griffen LM, Guinee DJ et al (2000) Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 95:1565–1571PubMed Bulaj ZJ, Phillips JD, Ajioka RS, Franklin MR, Griffen LM, Guinee DJ et al (2000) Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 95:1565–1571PubMed
258.
Zurück zum Zitat Vieira FM, Aoki V, Oliveira ZN, Martins JE (2010) Study of direct immunofluorescence, immunofluorescence mapping and light microscopy in porphyria cutanea tarda. An Bras Dermatol 85:827–837PubMedCrossRef Vieira FM, Aoki V, Oliveira ZN, Martins JE (2010) Study of direct immunofluorescence, immunofluorescence mapping and light microscopy in porphyria cutanea tarda. An Bras Dermatol 85:827–837PubMedCrossRef
259.
Zurück zum Zitat Singal AK, Kormos-Hallberg C, Lee C, Sadagoparamanujam VM, Grady JJ, Freeman DH Jr, Anderson KE (2012) Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol 10:1402–1409PubMedPubMedCentralCrossRef Singal AK, Kormos-Hallberg C, Lee C, Sadagoparamanujam VM, Grady JJ, Freeman DH Jr, Anderson KE (2012) Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol 10:1402–1409PubMedPubMedCentralCrossRef
260.
Zurück zum Zitat Singal AK, Kormos-Hallberg C, Lee C et al (2012) Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol 10:1402PubMedPubMedCentralCrossRef Singal AK, Kormos-Hallberg C, Lee C et al (2012) Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol 10:1402PubMedPubMedCentralCrossRef
261.
Zurück zum Zitat Monastirli A, Georgiou S, Bolsen K et al (1999) Treatment of porphyria cutanea tarda with oral thalidomide. Skin Pharmacol Appl Ski Physiol 12:305CrossRef Monastirli A, Georgiou S, Bolsen K et al (1999) Treatment of porphyria cutanea tarda with oral thalidomide. Skin Pharmacol Appl Ski Physiol 12:305CrossRef
262.
Zurück zum Zitat Ayres S Jr, Mihan R (1978) Porphyria cutanea tarda: response to vitamin E. A review and two case reports. Cutis 22:50PubMed Ayres S Jr, Mihan R (1978) Porphyria cutanea tarda: response to vitamin E. A review and two case reports. Cutis 22:50PubMed
263.
Zurück zum Zitat Ballantyne JA, Hooper G (2004) The hand and diabetes. Curr Orthop 18:118–125CrossRef Ballantyne JA, Hooper G (2004) The hand and diabetes. Curr Orthop 18:118–125CrossRef
264.
Zurück zum Zitat Ravindran Rajendran S, Bhansali A, Walia R et al (2011) Prevalence and pattern of hand soft-tissue changes in type 2 diabetes mellitus. Diabetes Metab 37:312–317PubMedCrossRef Ravindran Rajendran S, Bhansali A, Walia R et al (2011) Prevalence and pattern of hand soft-tissue changes in type 2 diabetes mellitus. Diabetes Metab 37:312–317PubMedCrossRef
265.
Zurück zum Zitat Chen LH, Li C-Y, Kuo LC, Wang L-Y, Kuo KN, Jou IM, Hou W-H (2015) Risk of hand syndromes in patients with diabetes mellitus. A population-based cohort study in Taiwan. Medicine 94:e1575PubMedPubMedCentralCrossRef Chen LH, Li C-Y, Kuo LC, Wang L-Y, Kuo KN, Jou IM, Hou W-H (2015) Risk of hand syndromes in patients with diabetes mellitus. A population-based cohort study in Taiwan. Medicine 94:e1575PubMedPubMedCentralCrossRef
266.
Zurück zum Zitat Al-Matubsi HY, Hamdan F, Alhanbali OA et al (2011) Diabetic hand syndromes as a clinical and diagnostic tool for diabetes mellitus patients. Diabetes Res Clin Pract 94:225–229PubMedCrossRef Al-Matubsi HY, Hamdan F, Alhanbali OA et al (2011) Diabetic hand syndromes as a clinical and diagnostic tool for diabetes mellitus patients. Diabetes Res Clin Pract 94:225–229PubMedCrossRef
267.
Zurück zum Zitat Somai P (2011) Limited joint mobility in diabetes mellitus: the clinical implications. J Musculoskel Med 28:118–124 Somai P (2011) Limited joint mobility in diabetes mellitus: the clinical implications. J Musculoskel Med 28:118–124
268.
Zurück zum Zitat Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S (2013) Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol 12:125PubMedPubMedCentralCrossRef Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S (2013) Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol 12:125PubMedPubMedCentralCrossRef
269.
Zurück zum Zitat Yokote K, Chanprasert S, Lee L, Eirich K, Takemoto M, Watanabe A et al (2017) WRN mutation update: mutation spectrum, patient registries, and translational prospects. Hum Mutat 38:7–15PubMedCrossRef Yokote K, Chanprasert S, Lee L, Eirich K, Takemoto M, Watanabe A et al (2017) WRN mutation update: mutation spectrum, patient registries, and translational prospects. Hum Mutat 38:7–15PubMedCrossRef
270.
Zurück zum Zitat Davis T, Brook AJ, Rokicki MJ, Bagley MC, Kipling D (2016) Evaluating the role of p38 MAPK in the accelerated cell senescence of Werner syndrome fibroblasts. Pharmaceuticals 9:23PubMedCentralCrossRef Davis T, Brook AJ, Rokicki MJ, Bagley MC, Kipling D (2016) Evaluating the role of p38 MAPK in the accelerated cell senescence of Werner syndrome fibroblasts. Pharmaceuticals 9:23PubMedCentralCrossRef
271.
Zurück zum Zitat Goto M, Ishikawa Y, Sugimoto M, Furuichi Y (2013) Werner syndrome: a changing pattern of clinical manifestations in Japan (1917–2008). BioScience Trends 7:13–22PubMed Goto M, Ishikawa Y, Sugimoto M, Furuichi Y (2013) Werner syndrome: a changing pattern of clinical manifestations in Japan (1917–2008). BioScience Trends 7:13–22PubMed
272.
273.
Zurück zum Zitat Lee YA, Stevens HP, Delaporte E, Wahn U, Reis A (2000) A gene for an autosomal dominant scleroatrophic syndrome predisposing to skin cancer (Huriez syndrome) maps to chromosome 4q23. Am J Hum Genet 66:326–330PubMedPubMedCentralCrossRef Lee YA, Stevens HP, Delaporte E, Wahn U, Reis A (2000) A gene for an autosomal dominant scleroatrophic syndrome predisposing to skin cancer (Huriez syndrome) maps to chromosome 4q23. Am J Hum Genet 66:326–330PubMedPubMedCentralCrossRef
274.
Zurück zum Zitat Massip L, Garand C, Paquet ER, Cogger VC, O’Reilly JN, Tworek L, Hatherell A, Taylor CG, Thorin E, Zahradka P, Le Couteur DG, Lebel M (2010) Vitamin C restores healthy aging in a mouse model for Werner syndrome. FASEB J 24:158–172PubMedCrossRef Massip L, Garand C, Paquet ER, Cogger VC, O’Reilly JN, Tworek L, Hatherell A, Taylor CG, Thorin E, Zahradka P, Le Couteur DG, Lebel M (2010) Vitamin C restores healthy aging in a mouse model for Werner syndrome. FASEB J 24:158–172PubMedCrossRef
275.
Zurück zum Zitat Tokita M, Kennedy SR, Risques RA, Chun SG, Pritchard C, Oshima J, Liu Y, Bryant-Greenwood PK, Welcsh P, Monnat RJ (2016) Werner syndrome through the lens of tissue and tumour genomics. Sci Rep 6:32038PubMedPubMedCentralCrossRef Tokita M, Kennedy SR, Risques RA, Chun SG, Pritchard C, Oshima J, Liu Y, Bryant-Greenwood PK, Welcsh P, Monnat RJ (2016) Werner syndrome through the lens of tissue and tumour genomics. Sci Rep 6:32038PubMedPubMedCentralCrossRef
276.
Zurück zum Zitat Kikuchi K, Hoashi T, Yazawa N, Tamaki K (2006) Pseudoscleroderma associated with cancer. Clin Exp Dermatol 31:381–383PubMedCrossRef Kikuchi K, Hoashi T, Yazawa N, Tamaki K (2006) Pseudoscleroderma associated with cancer. Clin Exp Dermatol 31:381–383PubMedCrossRef
277.
Zurück zum Zitat Juarez M, Marshall R, Denton C, Evely R (2008) Paraneoplastic scleroderma secondary to hairy cell leukaemia successfully treated with cladribine. Rheumatology 47:1734–1735PubMedCrossRef Juarez M, Marshall R, Denton C, Evely R (2008) Paraneoplastic scleroderma secondary to hairy cell leukaemia successfully treated with cladribine. Rheumatology 47:1734–1735PubMedCrossRef
278.
Zurück zum Zitat Querfeld C, Sollberg S, Huerkamp C, Eckes B, Krieg T (2000) Pseudoscleroderma associated with lung cancer: correlation of collagen typ 1 and connective tissue growth factor gene expression. Br J Dermatol 142:1228–1233PubMedCrossRef Querfeld C, Sollberg S, Huerkamp C, Eckes B, Krieg T (2000) Pseudoscleroderma associated with lung cancer: correlation of collagen typ 1 and connective tissue growth factor gene expression. Br J Dermatol 142:1228–1233PubMedCrossRef
279.
Zurück zum Zitat Jedlickova H, Durčanská V, Vašků V (2016) Paraneoplastic scleroderma: are there any clues? Acta Dermatovenerol Croat 24:78–80PubMed Jedlickova H, Durčanská V, Vašků V (2016) Paraneoplastic scleroderma: are there any clues? Acta Dermatovenerol Croat 24:78–80PubMed
280.
Zurück zum Zitat Marek M, Rudny R (2016) Scleroderma of geriatric age and scleroderma-like paraneoplastic syndrome—description of two cases. Reumatologia 54:91–94PubMedPubMedCentralCrossRef Marek M, Rudny R (2016) Scleroderma of geriatric age and scleroderma-like paraneoplastic syndrome—description of two cases. Reumatologia 54:91–94PubMedPubMedCentralCrossRef
281.
Zurück zum Zitat Allen JA, Peterson A, Sufit R et al (2011) Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. Arthritis Rheum 63:3633–3639PubMedCrossRef Allen JA, Peterson A, Sufit R et al (2011) Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. Arthritis Rheum 63:3633–3639PubMedCrossRef
282.
Zurück zum Zitat Rongioletti F, Rebora A (1992) Cutaneous toxic mucinosis. J Am Acad Dermatol 26:788–790CrossRef Rongioletti F, Rebora A (1992) Cutaneous toxic mucinosis. J Am Acad Dermatol 26:788–790CrossRef
283.
Zurück zum Zitat D’Cruz D (2000) Autoimmune diseases associated with drugs, chemicals and environmental factors. Toxicol Lett 112:421–432PubMedCrossRef D’Cruz D (2000) Autoimmune diseases associated with drugs, chemicals and environmental factors. Toxicol Lett 112:421–432PubMedCrossRef
284.
Zurück zum Zitat Foti R, Leonardi R, Rondinone R et al (2008) Scleroderma-like disorders. Autoimmun Rev 7:331–339PubMedCrossRef Foti R, Leonardi R, Rondinone R et al (2008) Scleroderma-like disorders. Autoimmun Rev 7:331–339PubMedCrossRef
285.
Zurück zum Zitat Kaufman LD, Gruber BL, Gomez-Reino JJ et al (1994) Fibrogenic growth factors in the eosinophilia–myalgia syndrome and the toxic oil syndrome. Arch Dermatol 130:41–47PubMedCrossRef Kaufman LD, Gruber BL, Gomez-Reino JJ et al (1994) Fibrogenic growth factors in the eosinophilia–myalgia syndrome and the toxic oil syndrome. Arch Dermatol 130:41–47PubMedCrossRef
286.
Zurück zum Zitat Sharma SK, Handa R, Sood R et al (2004) Bleomycin-induced scleroderma. J Assoc Physicians India 52:76–77PubMed Sharma SK, Handa R, Sood R et al (2004) Bleomycin-induced scleroderma. J Assoc Physicians India 52:76–77PubMed
287.
Zurück zum Zitat Niklas K, Niklas AA, Majewski D, Puszczewicz M (2016) Rheumatic diseases induced by drugs and environmental factors: the state-of-the-art—part one. Reumatologia 54:122–127PubMedPubMedCentralCrossRef Niklas K, Niklas AA, Majewski D, Puszczewicz M (2016) Rheumatic diseases induced by drugs and environmental factors: the state-of-the-art—part one. Reumatologia 54:122–127PubMedPubMedCentralCrossRef
Metadaten
Titel
Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review
verfasst von
Caterina Ferreli
Giulia Gasparini
Aurora Parodi
Emanuele Cozzani
Franco Rongioletti
Laura Atzori
Publikationsdatum
16.07.2017
Verlag
Springer US
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 3/2017
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-017-8625-4

Weitere Artikel der Ausgabe 3/2017

Clinical Reviews in Allergy & Immunology 3/2017 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

HNO-Op. auch mit über 90?

16.04.2024 HNO-Chirurgie Nachrichten

Mit Blick auf das Risiko für Komplikationen nach elektiven Eingriffen im HNO-Bereich scheint das Alter der Patienten kein ausschlaggebender Faktor zu sein. Entscheidend ist offenbar, wie fit die Betroffenen tatsächlich sind.

Intrakapsuläre Tonsillektomie gewinnt an Boden

16.04.2024 Tonsillektomie Nachrichten

Gegenüber der vollständigen Entfernung der Gaumenmandeln hat die intrakapsuläre Tonsillektomie einige Vorteile, wie HNO-Fachleute aus den USA hervorheben. Sie haben die aktuelle Literatur zu dem Verfahren gesichtet.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.